KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
CV Kol pour Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: Statistiques d'influence
Rapport d'exécution
| Concept | World rank |
|---|---|
| probability cdr | #1 |
| fviii normal levels | #1 |
| venography feasibility | #1 |
| prescriptionbased | #1 |
| vte day | #1 |
| laalleles platelets | #1 |
| pregnancyrelated complications relatives | #1 |
| proportion pulmonary embolism | #1 |
| principal safety | #1 |
| org aptt | #1 |
| variable d‐dimer thresholds | #1 |
| intravenous unfractionated | #1 |
| outpatients symptomatic dvt | #1 |
| simplified wells rule | #1 |
| replacement vka | #1 |
| symptomatic recurrent | #1 |
| quantitative ddimer test | #1 |
| animal female heparin | #1 |
| fetal loss miscarriage | #1 |
| lmwh plasma levels | #1 |
| venous thromboembolism episode | #1 |
| failure diagnostic management | #1 |
| successful attenuation | #1 |
| desogestrelcontaining coagulation factors | #1 |
| venography tests | #1 |
| risk homozygous women | #1 |
| alternative diagnoses patients | #1 |
| dvt impedance plethysmography | #1 |
| carriers thrombophilic defects | #1 |
| smoking patency | #1 |
| adjunct thrombolysis | #1 |
| laalleles | #1 |
| idraparinux standard therapy | #1 |
| dvt symptomatic | #1 |
| plateletactivating antibodies risk | #1 |
| anticoagulants double | #1 |
| rule cdr | #1 |
| wells rule exclusion | #1 |
| vte difference | #1 |
| symptomatic pts | #1 |
| vka treatment treatment | #1 |
| matisse clinical trials | #1 |
| loss subsequent pregnancy | #1 |
| uesvt median | #1 |
| cancer patients cvcs | #1 |
| antithrombotic prescriptions adherence | #1 |
| einsteindvt | #1 |
| uesvt patients | #1 |
| age recurrent vte | #1 |
| management study | #1 |
| 95 elevated ctni | #1 |
| recurrence major bleeding | #1 |
| diagnostic strategies strategies | #1 |
| wellscdrscore | #1 |
| diagnostic strategy primary | #1 |
| submassive elevated ctni | #1 |
| levels procoagulant factors | #1 |
| 3 rfviia | #1 |
| strategies ultrasonography | #1 |
| gentamicin patients netilmicin | #1 |
| 12 kg1 enoxaparin | #1 |
| safety clinical utility | #1 |
| prothrombin 20210a mutation | #1 |
| pharmacological methods prophylaxis | #1 |
| 50 years combination | #1 |
| 0·2 3633 patients | #1 |
| patients protein deficiencies | #1 |
| clinical presentation category | #1 |
| elevated fviii | #1 |
| idraparinux recurrent thromboembolism | #1 |
| beta thromboglobulin org | #1 |
| 5mg apixaban | #1 |
| non‐invasive diagnostic work‐up | #1 |
| 547253 | #1 |
| study ecq | #1 |
| factual hemorrhage heparin | #1 |
| noacs prevention | #1 |
| recurrent vte statin | #1 |
| coagulationinhibiting | #1 |
| inr range ttr | #1 |
| vte occurred | #1 |
| 7268 patients suspected | #1 |
| ultrasound strategies patients | #1 |
| reported incidence vte | #1 |
| treatment cumulative incidence | #1 |
| 123362 | #1 |
| tinaquant assay comparison | #1 |
| scores riete score | #1 |
| inherited thrombophilia patients | #1 |
| rivaroxaban acute dvt | #1 |
| quantitative ddimer tests | #1 |
| pulmonary embolism tests | #1 |
| ctscanreading | #1 |
| scenarioanalysis | #1 |
| fondaparinux rfviia injection | #1 |
| fviii concentration | #1 |
| 8h flight | #1 |
| 3633 patients edoxabantreated | #1 |
| proportion 75 years | #1 |
| activecontrol placebo | #1 |
| venous thrombosis recurrence | #1 |
| recommendations dvt | #1 |
| intensity vkas doacs | #1 |
| mdct expert radiologist | #1 |
| 7268 patients | #1 |
| elevated ctni patients | #1 |
| recurrent vte doacs | #1 |
| probability normal | #1 |
| protein mortality | #1 |
| abnormal ipg | #1 |
| patients laalleles | #1 |
| dvt 56 | #1 |
| questionnaires thrombosis | #1 |
| 2479 relatives | #1 |
| dose rnapc2 | #1 |
| comparison vidas assay | #1 |
| orthopedic surgery netherlands | #1 |
| 5‐snp scores | #1 |
| nonhigh cdr | #1 |
| elevated fviii patients | #1 |
| evaluable patients 95 | #1 |
| relatives normal fviii | #1 |
| ambulatory computers | #1 |
| ddimer test combination | #1 |
| weight heparinoid | #1 |
| deficiency proteins | #1 |
| annual incidence patients | #1 |
| uesvt recurrent vte | #1 |
| residual thrombotic mass | #1 |
| fviii vte | #1 |
| realtime bmode ultrasonography | #1 |
| systematic search cteph | #1 |
| tb402 50 | #1 |
| survival lmwh | #1 |
| ufh grade | #1 |
| risk percentage points | #1 |
| doses 75 microg | #1 |
| thrombophilia late loss | #1 |
| presenting vte location | #1 |
| cstatistic model discrimination | #1 |
| total vte patients | #1 |
| 0·620·74 | #1 |
| prophylaxis idraparinux | #1 |
| test venography | #1 |
| hellp syndrome mutations | #1 |
| cancer edoxaban | #1 |
| axa activity 5 | #1 |
| patients idraparinux | #1 |
| original wells | #1 |
| evaluable patients apixaban | #1 |
| travellers thrombosis | #1 |
| ldf diagnosis | #1 |
| heparin vitamin antagonist | #1 |
| ldf cus | #1 |
| sgs pretest probability | #1 |
| threemonth incidence | #1 |
| patients treatment duration | #1 |
| rnapc2 groups placebo | #1 |
| lowmolecularweight heparin category | #1 |
| probability ventilation | #1 |
| frequency venous thromboembolism | #1 |
| 3 idraparinux | #1 |
| rnapc2 inhibition | #1 |
| nadroparin patients | #1 |
| dose daily edoxaban | #1 |
| aged nadroparin | #1 |
| cancer patients uedvt | #1 |
| patients advanced malignancy | #1 |
| cart lower levels | #1 |
| standard therapy months | #1 |
| org heparin | #1 |
| patients uedvt uesvt | #1 |
| embolism randomized | #1 |
| standard treatment idraparinux | #1 |
| nadroparin aspirin | #1 |
| recurrent thrombosis pts | #1 |
| sensitivity 100 percent | #1 |
| obese controls difference | #1 |
| pvo qscan | #1 |
| pulmonary embolism life | #1 |
| wellsrule | #1 |
| segmental subsegmental | #1 |
| current practise | #1 |
| amplify trial | #1 |
| riskstroponin | #1 |
| monoclonal antibodies apc | #1 |
| long haul flights | #1 |
| fibrinolysis levels | #1 |
| edoxabantreated | #1 |
| ufh grade 1a | #1 |
| types major bleeding | #1 |
| oral edoxaban dose | #1 |
| major bleeds vka | #1 |
| enoxaparin vkas | #1 |
| longhaul flight | #1 |
| compression ultrasonography presentation | #1 |
| dimer result | #1 |
| vitamin antagonists treatment | #1 |
| abdominal pelvic strategies | #1 |
| combination cdr | #1 |
| d‐dimer test | #1 |
| pulmonary embolism | #1 |
| patients normal tests | #1 |
| ventricular dysfunction edoxaban | #1 |
| 750 μg l1 | #1 |
| 95 intracranial | #1 |
| rabinov | #1 |
| cdr ddimer levels | #1 |
| chest perfusion scan | #1 |
| intravenous injections lmwh | #1 |
| —brachial | #1 |
| normal lung scan | #1 |
| hokusaivte trial | #1 |
| heparin org 10172 | #1 |
| heparin initial | #1 |
| timerequirement | #1 |
| extra hospital visits | #1 |
| 500 org | #1 |
| sustained antithrombotic effects | #1 |
| administration lmwh | #1 |
| women elevated levels | #1 |
| dimer test | #1 |
| somittrial | #1 |
| level loss patency | #1 |
| relevant major | #1 |
| clinical uedvt | #1 |
| dvt 69 | #1 |
| ankle brachial prevalence | #1 |
| duration heparin treatment | #1 |
| hemorrhage heparin | #1 |
| rtap lmwh | #1 |
| pulmonary embolism role | #1 |
| ultrasonography dvt | #1 |
| aged venous | #1 |
| carriers pulmonary embolism | #1 |
| patients acute recurrent | #1 |
| method factor | #1 |
| safety 60 dose | #1 |
| lmwh departments | #1 |
| polyethylenglycolhirudin | #1 |
| enoxaparin vkas treatment | #1 |
| uesvt uedvt | #1 |
| vte addition | #1 |
| puerperium diagnostic suspicion | #1 |
| normal venogram | #1 |
| fetal loss carriers | #1 |
| therapeutic doses lmwh | #1 |
| oral administration bsf | #1 |
| 208791 | #1 |
| pulmonary embolism basis | #1 |
| coagulation factors markers | #1 |
| absolute annual incidences | #1 |
| conventional therapy enoxaparin | #1 |
| cancer patients ufh | #1 |
| prolactin venous thrombosis | #1 |
| selective beta‐blocker treatment | #1 |
| vte location | #1 |
| ipe expert radiologists | #1 |
| rnapc2 patients | #1 |
| tomography angiography vte | #1 |
| cdr ddimer test | #1 |
| vka share | #1 |
| abnormal vaginal bleeding | #1 |
| fviii homocysteine | #1 |
| anticoagulant treatment vte | #1 |
| pulmonary angiography study | #1 |
| easier monitoring | #1 |
| edoxaban dalteparin | #1 |
| neoplasms heparin | #1 |
| postthrombotic symptoms patients | #1 |
| vte risk coc | #1 |
| acute recurrent patients | #1 |
| feasibility venography | #1 |
| dalteparin vte treatment | #1 |
| reocclusion antithrombotic drug | #1 |
| extended treatment edoxaban | #1 |
| vte trial | #1 |
| probability lung scan | #1 |
| venous thromboembolism idraparinux | #1 |
| incidental symptomatic vte | #1 |
| death venous thromboembolism | #1 |
| lmwh immobilization | #1 |
| outcome clinically | #1 |
| dose response apixaban | #1 |
| low levels ft4 | #1 |
| anticoagulants probability | #1 |
| rule exclusion | #1 |
| patients tb402 | #1 |
| presence venous thrombosis | #1 |
| intestinal microbiota coagulation | #1 |
| studies 3 months | #1 |
| failure cip | #1 |
| venous thrombosis hyperglycemia | #1 |
| mortality postthrombotic symptoms | #1 |
| atherosclerosis hemophilia patients | #1 |
| reduceddose noacs | #1 |
| false normal | #1 |
| tests pulmonary embolism | #1 |
| controlledstudy | #1 |
| 560 pharmacies | #1 |
| acute treatment lmwh | #1 |
| 36 papers | #1 |
| vte arterial | #1 |
| respondents lmwh | #1 |
| category perelated death | #1 |
| dvt costs | #1 |
| thiazoles venous | #1 |
| ft4 level patients | #1 |
| heparin vitamin | #1 |
| combination cdrscore | #1 |
| fetal loss stillbirth | #1 |
| patients examiner | #1 |
| fxainhibitors vka recipients | #1 |
| compression ultrasound dvt | #1 |
| patients advanced prostate | #1 |
| cdrs patients | #1 |
| randomized studies efficacy | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| idraparinux vte | #1 |
| heparins data | #1 |
| age∗10μg | #1 |
| thromboembolism 3 | #1 |
| warfarin cancer patients | #1 |
| prothrombin individuals | #1 |
| presenting location vte | #1 |
| included patients study | #1 |
| failure rate efficiency | #1 |
| death vte studies | #1 |
| messages justification | #1 |
| presentation major | #1 |
| antidote vitamin | #1 |
| deep vein thrombosis | #1 |
| leg ultrasonography patients | #1 |
| mutation arg506 | #1 |
| thrombosis vitamin | #1 |
| pulmonary embolism idraparinux | #1 |
| synthetic selective factor | #1 |
| elevated fviii age | #1 |
| phase doacs | #1 |
| doacs anatomical extent | #1 |
| avidin idrabiotaparinux | #1 |
| progression vte | #1 |
| wells cdr | #1 |
| clinically suspected uedvt | #1 |
| probabilityscan | #1 |
| reduceddose noacs stroke | #1 |
| gogh dvt trial | #1 |
| consensus strategy strategy | #1 |
| idraparinux 25 | #1 |
| incidence ctni | #1 |
| efficacy outcome | #1 |
| selective ddimer thresholds | #1 |
| embolism suspected | #1 |
| hokusai‐vte cancer study | #1 |
| xageneration | #1 |
| symptomatic legs dvt | #1 |
| achieved inr patients | #1 |
| 6 months avidin | #1 |
| suspected symptomatic | #1 |
| venous thrombosis mutations | #1 |
| heparins cancer spread | #1 |
| referral basis | #1 |
| association protein levels | #1 |
| rfviia idraparinux | #1 |
| ddimer levels cdr | #1 |
| doubleheterozygotes | #1 |
| dvt 3 | #1 |
| efficacy vte | #1 |
| heparin acenocoumarol | #1 |
| idraparinux placebo | #1 |
| cip diagnostic management | #1 |
| local radiologist experts | #1 |
| crptest | #1 |
| lmwh edoxaban | #1 |
| progression svt | #1 |
| initial treatment patients | #1 |
| survival fondaparinux | #1 |
| excluding pulmonary | #1 |
| 20210a mutation | #1 |
| patients ivte | #1 |
| proximal extent ipe | #1 |
| topic thrombophlebitis | #1 |
| vka netherlands | #1 |
| malignancy achieved inr | #1 |
| intracranial clinical presentation | #1 |
| heparin survival | #1 |
| venous thrombus growth | #1 |
| hokusai vte cancer | #1 |
| ultrasonography diagnostic | #1 |
| superficial thrombophlebitis incidence | #1 |
| qscan | #1 |
| venous thrombosis pregnancy | #1 |
| 2630 pilots | #1 |
| graft patency patency | #1 |
| travel‐related venous thrombosis | #1 |
| matisse dvt | #1 |
| patients retropubic prostatectomy | #1 |
| year prophylaxis | #1 |
| rivaroxaban replacement | #1 |
| avidin vte | #1 |
| older patients cdr | #1 |
| doacs cirrhosis patients | #1 |
| simplified rule proportion | #1 |
| normotensive patients studies | #1 |
| vte study | #1 |
| avidin placebo | #1 |
| dalteparin 6 months | #1 |
| 00515 | #1 |
| idraparinux 6 months | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| ivte | #1 |
| standard therapy rivaroxaban | #1 |
| current comprehensions | #1 |
| edoxaban warfarin groups | #1 |
| rnapc2 groups | #1 |
| vte fatal | #1 |
| category fxainhibitors | #1 |
| placebo 25mg apixaban | #1 |
| excluded pulmonary | #1 |
| simple diagnostic strategy | #1 |
| baseline characteristics duration | #1 |
| amplify trial apixaban | #1 |
| lmwh rtap | #1 |
| time recombinant | #1 |
| proximal location ipe | #1 |
| pulmonary embolism metaanalysis | #1 |
| treatment venous | #1 |
| 3633 patients edoxaban | #1 |
| departments pharmacological prophylaxis | #1 |
| khorana | #1 |
| ldfr symptomatic legs | #1 |
| clinical probability patients | #1 |
| carriers relative risks | #1 |
| respondents 60 | #1 |
| lmwh delivery | #1 |
| presentation category | #1 |
| combined training gps | #1 |
| scores occult cancer | #1 |
| heparins vitamin antagonists | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| factor viii homocysteine | #1 |
| uesvt mortality | #1 |
| dimer clinical | #1 |
| qscan 3 weeks | #1 |
| relatives antithrombin | #1 |
| thrice daily gentamicin | #1 |
| rabinovpaulin | #1 |
| avws prevalence | #1 |
| clinical probability risk | #1 |
| bleeding risk treatment | #1 |
| cancer 145 patients | #1 |
| double heterozygous carriers | #1 |
| single‐detector row | #1 |
| prevention topic guidelines | #1 |
| coagulation fibrinolytic proteins | #1 |
| decisions duration | #1 |
| compression ultrasonography detection | #1 |
| individualized duration | #1 |
| wells clinical | #1 |
| rhir lmwh | #1 |
| lmwhs 95 | #1 |
| vitamin anticoagulants | #1 |
| ddimer test result | #1 |
| thrombosis vte | #1 |
| control anticardiolipin antibodies | #1 |
| absolute thrombotic risk | #1 |
| bleeding rates quality | #1 |
| safety outcome | #1 |
| patients khorana | #1 |
| patients wells rule | #1 |
| idrabiotaparinux idraparinux | #1 |
| bleeding einstein | #1 |
| dalteparin major bleeding | #1 |
| symptomatic recurrent vte | #1 |
| cancer patients patients | #1 |
| abelacimab | #1 |
| vte procoagulant activity | #1 |
| vkas lmwh | #1 |
| p0424 | #1 |
| rivaroxaban lmwh vka | #1 |
| local radiologist | #1 |
| treatment experimental thrombosis | #1 |
| lmprovement | #1 |
| rivaroxaban standard therapy | #1 |
| ili score | #1 |
| warfarin cstatistic | #1 |
| venous thrombosis vwf | #1 |
| guidelines abi | #1 |
| efficacy heparin therapy | #1 |
| rule dimer | #1 |
| calf dvt ultrasound | #1 |
| infections gentamicin | #1 |
| relatives elevated levels | #1 |
| scan pulmonary embolism | #1 |
| 12 months edoxaban | #1 |
| hokusaivte study | #1 |
| fviii venous thromboembolism | #1 |
| oral rivaroxaban treatment | #1 |
| isolated deficiencies proteins | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| anticoagulation period | #1 |
| thromboembolism treated | #1 |
| suspected perfusion scan | #1 |
| severity clinical presentation | #1 |
| relatives tafi levels | #1 |
| heparins cancer patients | #1 |
| uedvt terms | #1 |
| mutation relatives | #1 |
| treat thrombosis | #1 |
| protecht shr | #1 |
| 393 patients warfarin | #1 |
| combination cdrs | #1 |
| cdrscore combination | #1 |
| protein levels mortality | #1 |
| clinically suspected dvt | #1 |
| aptt org | #1 |
| upper extremity uedvt | #1 |
| calfvein thrombi | #1 |
| lmwh venous thrombosis | #1 |
| equinox study | #1 |
| einstein dvt patients | #1 |
| normal dimer | #1 |
| recurrent dvt dvt | #1 |
| previous surveys netherlands | #1 |
| embolism sensitivity | #1 |
| vkas efficacy | #1 |
| edoxaban east asian | #1 |
| vitamin antagonists time | #1 |
| ultrasonography leg veins | #1 |
| apixaban extended treatment | #1 |
| s1p1activation | #1 |
| ultrasound compression ultrasound | #1 |
| leg veins patients | #1 |
| embolism wells | #1 |
| preferred oral anticoagulant | #1 |
| women factor leiden | #1 |
| doac recipients | #1 |
| chest perfusion scintigraphy | #1 |
| intrinsic coagulation vivo | #1 |
| patency smokers | #1 |
| diagnostic strategies patients | #1 |
| recurrence bleeding risk | #1 |
| standalone ddimer testing | #1 |
| wound haematoma | #1 |
| severe presentation patients | #1 |
| pulmonary embolism studies | #1 |
| unexplained dvt | #1 |
| orthopedic thromboprophylaxis | #1 |
| normal ddimer result | #1 |
| subcutaneous nadroparin placebo | #1 |
| subsequent symptomatic cancer | #1 |
| inr studies | #1 |
| idraparinux patients | #1 |
| patients deep | #1 |
| svt lmwh | #1 |
| relatives mutation | #1 |
| lmwh replacement | #1 |
| perelated death classification | #1 |
| factor viii relatives | #1 |
| impedance thrombophlebitis | #1 |
| extensive screening cancer | #1 |
| daily dalteparin treatment | #1 |
| fviii hyperhomocysteinemia | #1 |
| initial heparin patients | #1 |
| pulmonary angiography strategies | #1 |
| acquired atiii deficiency | #1 |
| heparins inhibition | #1 |
| chromogenic endotoxin | #1 |
| 97 compression ultrasonography | #1 |
| diagnostic management patients | #1 |
| cdr normal | #1 |
| pioped study study | #1 |
| hyperhomocysteinemia relatives | #1 |
| idraparinux vitamin antagonist | #1 |
| subsequent diagnosis malignancy | #1 |
| nadroparin therapeutic dose | #1 |
| silent dvt | #1 |
| association travel | #1 |
| wellscdr | #1 |
| studies ttr | #1 |
| doacs initial heparin | #1 |
| suspected deep | #1 |
| pulmonary embolism fondaparinux | #1 |
| bmi fondaparinux | #1 |
| standardintensity vkas | #1 |
| undvt | #1 |
| ventilation scan chest | #1 |
| timeperiod | #1 |
| tb402 enoxaparin | #1 |
| practiceassistants | #1 |
| plasma concentration fviii | #1 |
| vte airline pilots | #1 |
| pvo ctscan | #1 |
| fxiaso enoxaparin | #1 |
| patients clinical probability | #1 |
| coagulation clinical | #1 |
| uedvt clinical | #1 |
| thrombo‐embolic events | #1 |
| presenting location women | #1 |
| initial heparin edoxaban | #1 |
| initial treatment dvt | #1 |
| patients unexplained dvt | #1 |
| cancer cdr | #1 |
| smoking graft patency | #1 |
| heparinoid | #1 |
| cdr dimer | #1 |
| normal levels fviii | #1 |
| departments orthopedic surgery | #1 |
| revascularisation procedures patients | #1 |
| cvc crt | #1 |
| ml1 ctpa | #1 |
| unexplained dvt patients | #1 |
| fondaparinux unfractionated | #1 |
| clinical decision rule | #1 |
| 0·2 edoxabantreated | #1 |
| adjusted dose ufh | #1 |
| united states rnapc2 | #1 |
| strategies abdominal pelvic | #1 |
| standardintensity vkas doacs | #1 |
| 378 patients edoxaban | #1 |
| single dose tb402 | #1 |
| women edoxaban | #1 |
| tests venography | #1 |
| rfviia fondaparinux | #1 |
| matisse trials | #1 |
| dvt anticoagulants | #1 |
| constans score | #1 |
| relative risks carriers | #1 |
| quantitative ddimer testing | #1 |
| perelated death category | #1 |
| ventilation lung scanning | #1 |
| hokusaivte trial patients | #1 |
| milliliter enoxaparin | #1 |
| wells rules | #1 |
| enoxaparin initial treatment | #1 |
| pyridines recurrence | #1 |
| controlled trials thrombophilia | #1 |
| presentation 1 week | #1 |
| noncarriers annual incidence | #1 |
| recurrent vte immobilization | #1 |
| cdrscore | #1 |
| cstatistic major bleeding | #1 |
| procoagulant factors levels | #1 |
| 9 incidence | #1 |
| efficacy conventional treatment | #1 |
| quantitative dimer | #1 |
| p0001 saline | #1 |
| early time recurrence | #1 |
| predefined outcomes | #1 |
| sspe proximal | #1 |
| edoxaban risk factors | #1 |
| elderly patients dvt | #1 |
| models development studies | #1 |
| enoxaparin primary efficacy | #1 |
| pulmonary embolism cdr | #1 |
| idraparinux versus | #1 |
| positive vte | #1 |
| death category | #1 |
| casedescription | #1 |
| ccus 4 | #1 |
| specificity pulmonary embolism | #1 |
| followup overt cancer | #1 |
| studies doac treatment | #1 |
| early discharge strategies | #1 |
| strategy abdominal pelvic | #1 |
| tsh antitpo | #1 |
| einsteinextension | #1 |
| wells simplified | #1 |
| acenocoumarol initial treatment | #1 |
| cus strategies | #1 |
| lowmolecularweight heparin treatment | #1 |
| 250 patients cancer | #1 |
| crp test patients | #1 |
| fxainhibitors | #1 |
| elderly outpatients combination | #1 |
| iii plg | #1 |
| oral anticoagulants phase | #1 |
| idraparinux | #1 |
| perfusion scan | #1 |
| nondiagnostic lung scan | #1 |
| obstetric complications relatives | #1 |
| incidence venous | #1 |
| flebography | #1 |
| endotoxemia tests | #1 |
| clinical probability exclusion | #1 |
| edoxaban cancer patients | #1 |
| patients mismatched scan | #1 |
| cancer patients cdr | #1 |
| fviii women | #1 |
| vte risk day | #1 |
| combination nonhigh cdr | #1 |
| anticoagulant treatment patients | #1 |
| probability categories | #1 |
| elevated biomarkers hospital | #1 |
| platelets iqr | #1 |
| exclusion pulmonary | #1 |
| clinically relevant disease | #1 |
| falsenormal | #1 |
| subcutaneous length life | #1 |
| simplified geneva score | #1 |
| guideline adherence justification | #1 |
| lowmolecularweight heparin 95 | #1 |
| ddimer result | #1 |
| category death | #1 |
| screening carriers | #1 |
| extended anticoagulation doacs | #1 |
| patients tests prevalence | #1 |
| double reports | #1 |
| apixaban conventional therapy | #1 |
| lmwh users incidence | #1 |
| cancer patients cancer | #1 |
| withheld | #1 |
| months standard therapy | #1 |
| patients reduceddose noacs | #1 |
| outcome recurrent | #1 |
| netherlands vka | #1 |
| ifngamma pselectin | #1 |
| acenocoumarol heparin | #1 |
| botticelli dvt dose‐ranging | #1 |
| heparin initial treatment | #1 |
| placebo rnapc2 | #1 |
| 15 lmwh | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| xainhibitors | #1 |
| travel venous thromboembolism | #1 |
| symptomatic venous | #1 |
| combination ddimer testing | #1 |
| pulmonary angiography ultrasonography | #1 |
| 2 diagnostic management | #1 |
| rate recurrent | #1 |
| limited screening 95 | #1 |
| protein resistance control | #1 |
| obese hemophilic patients | #1 |
| 25mg apixaban | #1 |
| analysis hokusai | #1 |
| prophylaxis crt | #1 |
| deepvein thrombosis incidence | #1 |
| carriers recurrence | #1 |
| ctscan qscan | #1 |
| ivte clinical practice | #1 |
| apixaban randomized patients | #1 |
| tb402 prevention | #1 |
| elevated levels fviii | #1 |
| vivo coagulation factor | #1 |
| prospective management study | #1 |
| crt cvc | #1 |
| individuals air travel | #1 |
| d‐dimer level | #1 |
| elevated cardiac troponins | #1 |
| wells rule primary | #1 |
| 69 conclusions | #1 |
| patients enoxaparin vkas | #1 |
| age multiple comorbidities | #1 |
| prediction models recurrence | #1 |
| 50 rivaroxaban | #1 |
| netherlands lmwh | #1 |
| 65±9years | #1 |
| anticoagulants chemotherapy | #1 |
| patients malignancy | #1 |
| poc test patients | #1 |
| molecular weight fondaparinux | #1 |
| 95 3633 patients | #1 |
| baseline pvo | #1 |
| major bleeding cancer | #1 |
| hokusai‐vte trial | #1 |
| influenza case patients | #1 |
| role exclusion | #1 |
| treatment idraparinux | #1 |
| reduceddose noacs warfarin | #1 |
| tb402 12 kg1 | #1 |
| cancer clinical presentation | #1 |
| safety idraparinux | #1 |
| lmwhmediated | #1 |
| suspected cdr | #1 |
| thrombophlebitis tomography | #1 |
| beneficial lmwh | #1 |
| ecq ankle brachial | #1 |
| doacs factor | #1 |
| enoxaparin heparin treatment | #1 |
| embolism radionuclide | #1 |
| pvoq | #1 |
| diagnosis deepvein thrombosis | #1 |
| ddimer test patients | #1 |
| asymptomatic extension | #1 |
| advanced malignancy | #1 |
| compression ultrasonography patients | #1 |
| patients initial heparin | #1 |
| 95ci tb402 | #1 |
| patients inherited thrombophilia | #1 |
| normal ddimer concentration | #1 |
| thrombophilia patients doacs | #1 |
| aptt org 10172 | #1 |
| vitamin antagonist patients | #1 |
| study centre duration | #1 |
| echocardiography normotensive patients | #1 |
| prevalence coagulation | #1 |
| bleeding risk lmwh | #1 |
| preference doacs | #1 |
| vka recipients | #1 |
| rfviia 3 | #1 |
| international thrombosis experts | #1 |
| 5395 patients | #1 |
| ddimer test | #1 |
| increasing levels ft4 | #1 |
| relatives normal levels | #1 |
| strategies diagnostic management | #1 |
| apc resistance tests | #1 |
| oral apixaban treatment | #1 |
| bleeding clinically | #1 |
| submassive incidence | #1 |
| uesvt | #1 |
| venous thromboembolism edoxaban | #1 |
| cdr physicians | #1 |
| enoxaparin tb402 | #1 |
| distal clots | #1 |
| treated vka | #1 |
| popliteal veins sensitivity | #1 |
| patients compression ultrasonography | #1 |
| idraparinux months | #1 |
| extended anticoagulation apixaban | #1 |
| clinically suspected cancer | #1 |
| patients antithrombotic prescriptions | #1 |
| 53 amputations | #1 |
| pulmonary embolism carriers | #1 |
| patients artificial graft | #1 |
| netherlands 5 years | #1 |
| apc resistance factor | #1 |
| relevant bleeding | #1 |
| rnapc2 united states | #1 |
| members symptomatic carriers | #1 |
| risk pulmonary embolism | #1 |
| subcutaneous idraparinux | #1 |
| predefined outcomes vte | #1 |
| thromboembolism relatives | #1 |
| uedvt recurrent vte | #1 |
| 5 years lmwh | #1 |
| 023 relatives | #1 |
| anticoagulant fondaparinux | #1 |
| 5 avidin infusion | #1 |
| acenocoumarol efficacy | #1 |
| compression ultrasonography | #1 |
| lmwh acute treatment | #1 |
| efficiency subgroups | #1 |
| gastrointestinal cancer edoxaban | #1 |
| rivaroxaban dvt treatment | #1 |
| tests prevalence abi | #1 |
| thrombosis normal | #2 |
| bleeding occurred | #2 |
| years 36 | #2 |
| compression doppler | #2 |
| interleukin‐10 response | #2 |
| 95 comparator individuals | #2 |
| bleeding complications treatment | #2 |
| safety pravastatin therapy | #2 |
| risk deep | #2 |
| mutations cleavage sites | #2 |
| n832 | #2 |
| incidental vte | #2 |
| pulmonary embolism purpose | #2 |
| death vte | #2 |
| vte elevated fviii | #2 |
| low‐molecular‐weight heparin | #2 |
| recombinant hirudin cgp | #2 |
| hellp syndrome prevalence | #2 |
| warfarintreated | #2 |
| 8 wk risk | #2 |
| arterial thrombotic disease | #2 |
| amadeus study | #2 |
| brain metastases doacs | #2 |
| heparin administered | #2 |
| khorana protecht | #2 |
| vte 1000 personyears | #2 |
| suspected pulmonary | #2 |
| vein compressibility | #2 |
| rfviia injection rfviia | #2 |
| influenza coagulation | #2 |
| relevant patient subgroups | #2 |
| normohomocysteinemic relatives | #2 |
| wells cdr patients | #2 |
| tinaquant vidas | #2 |
| risk khorana | #2 |
| ufh survival | #2 |
| exclude pulmonary | #2 |
| blood coagulation rnapc2 | #2 |
| patients oral factor | #2 |
| surgical casts | #2 |
| enoxaparin difference | #2 |
| 95 dvt | #2 |
| pregnancy venous thrombosis | #2 |
| embolism deep | #2 |
| enoxaparin warfarin | #2 |
| mild risk factor | #2 |
| factor iia | #2 |
| raskob | #2 |
| current clinical challenges | #2 |
| referred patients secondary | #2 |
| lower clinical utility | #2 |
| sr34006 | #2 |
| rnapc2 doses | #2 |
| travel venous | #2 |
| risk anticoagulation therapy | #2 |
| serum tnf activity | #2 |
| computed venous | #2 |
| thyroid hormone coagulation | #2 |
| subcutaneous length | #2 |
| duration anticoagulant | #2 |
| levels coagulation factors | #2 |
| plasma d‐dimer concentration | #2 |
| gcpg | #2 |
| resource utilisation treatment | #2 |
| impedance plethysmography diagnosis | #2 |
| undiagnosed malignancy | #2 |
| bleeding edoxaban | #2 |
| statins recurrent vte | #2 |
| endotoxininduced activation coagulation | #2 |
| months 25 | #2 |
| clinical pretest probability | #2 |
| embolism safely | #2 |
| blood coagulation inhibition | #2 |
| age‐adjusted d‐dimer testing | #2 |
| pentasaccharide fondaparinux | #2 |
| crd42017056309 | #2 |
| treated anticoagulants | #2 |
| administration rviia | #2 |
| global public awareness | #2 |
| lmwh efficacy | #2 |
| pregnancy coc | #2 |
| normal ddimer test | #2 |
| heparin effective | #2 |
| treatment ttr | #2 |
| ddimer determination | #2 |
| c1173t dimorphism | #2 |
| vidas assay | #2 |
| principal safety outcome | #2 |
| relation coagulation factors | #2 |
| rnapc2 | #2 |
| comparator individuals 95 | #2 |
| thrombophilic disorders | #2 |
| prothrombin pulmonary embolism | #2 |
| gauge plethysmography | #2 |
| single administration tb402 | #2 |
| inflammation neutrophils thrombosis | #2 |
| 20210a mutations | #2 |
| cancer addition | #2 |
| measurement ankle brachial | #2 |
| primary efficacy outcome | #2 |
| presentation dvt | #2 |
| 8292 patients | #2 |
| apixaban lmwh vka | #2 |
| oral direct inhibitors | #2 |
| failure rate strategy | #2 |
| venographically | #2 |
| suspected pulmonary embolism | #2 |
| heparin treatment influenza | #2 |
| computerized impedance | #2 |
| standardised time intervals | #2 |
| model cancer patients | #2 |
| cancer recurrent vte | #2 |
| annual incidences | #2 |
| extended constans score | #2 |
| uedvt cancer patients | #2 |
| major bleeding intermediate | #2 |
| plasma concentrations endotoxin | #2 |
| quality warfarin treatment | #2 |
| plasmin activity inhibition | #2 |
| patients abi measurement | #2 |
| apixaban enoxaparin warfarin | #2 |
| ageadjusted ddimer testing | #2 |
| deficiencies proteins | #2 |
| biomarkers casecontrol studies | #2 |
| negative ageadjusted ddimer | #2 |
| regression pravastatin | #2 |
| lmwh users | #2 |
| lowmolecularweight heparin women | #2 |
| pravastatin therapy children | #2 |
| vte 12 | #2 |
| levothyroxine exposure | #2 |
| intrinsic cascade | #2 |
| protein rnapc2 | #2 |
| 95 0·2 | #2 |
| rule combined | #2 |
| cha2ds2vasc nri | #2 |
| amuse strategy | #2 |
| performance constans rule | #2 |
| subsegmental emboli | #2 |
| incidence recurrent | #2 |
| heparin nadroparin | #2 |
| outcome symptomatic | #2 |
| ddimer assay | #2 |
| fvl carriers carriers | #2 |
| treated edoxaban | #2 |
| ultrasonography patients | #2 |
| impedance plethysmography patients | #2 |
| euro138 | #2 |
| embolism primary | #2 |
| ufh 6 months | #2 |
| hokusai vtecancer study | #2 |
| crnm bleeds | #2 |
| patients khorana score | #2 |
| clinical prediction model | #2 |
| influenza prothrombotic state | #2 |
| beta‐receptor blockade | #2 |
| secondary strategies | #2 |
| medscape | #2 |
| nct00633893 | #2 |
| patients prior vte | #2 |
| exclusion pulmonary embolism | #2 |
| life treatment duration | #2 |
| rivaroxaban 30 bid | #2 |
| recombinant nematode | #2 |
| exposure flights | #2 |
| endogenous activated protein | #2 |
| scan normal | #2 |
| absolute incidence | #2 |
| mutations propeptide | #2 |
| f5 r506q | #2 |
| patients low probability | #2 |
| thromboembolism thrombophilia | #2 |
| decision rule | #2 |
| uedvt efficiency | #2 |
| angioplasty clopidogrel | #2 |
| hasbled score hemorr2hages | #2 |
| patients hemorr2hages | #2 |
| screening fvl | #2 |
| hospitalbased strategies | #2 |
| employees longhaul flight | #2 |
| women therapeutic doses | #2 |
| fviii increased risk | #2 |
| n1423 | #2 |
| primary healthcare secondary | #2 |
| uptake noacs | #2 |
| concomitant thrombophilic | #2 |
| recurrence thromboembolism | #2 |
| limits cancer | #2 |
| secondary efficiency | #2 |
| major bleeding cindexes | #2 |
| central localization | #2 |
| score dimer | #2 |
| diagnostic lung | #2 |
| acquired antithrombin | #2 |
| clinical probability estimate | #2 |
| pulmonary embolism efficacy | #2 |
| dimer thresholds | #2 |
| thromboinflammation cardiovascular disease | #2 |
| incidental venous | #2 |
| test cancer | #2 |
| antagonists vka | #2 |
| anticoagulated patients permanent | #2 |
| uedvt performance | #2 |
| efficiency diagnostic strategies | #2 |
| cdr wells cdr | #2 |
| rivaroxaban thiazoles | #2 |
| hokusai vte | #2 |
| fibrinolysis pentoxifylline | #2 |
| nonpermanent heart failure | #2 |
| venous thromboembolism enoxaparin | #2 |
| ate cancer patients | #2 |
| idraparinux vitamin | #2 |
| coagulation fibrinolytic | #2 |
| adapted ddimer thresholds | #2 |
| heparin compounds | #2 |
| events severe | #2 |
| symptomatic outpatients | #2 |
| ventilation scanning | #2 |
| simplired test | #2 |
| alife study | #2 |
| vitamin antagonists quality | #2 |
| vte svt | #2 |
| wells cdr cdr | #2 |
| duration anticoagulant treatment | #2 |
| 3306 patients | #2 |
| vitamin antagonist rivaroxaban | #2 |
| suspected upper | #2 |
| rule proportion | #2 |
| 95 cancer patients | #2 |
| mutation 35 | #2 |
| patients peripheral graft | #2 |
| primary hospitalbased strategies | #2 |
| cdr variables cdr | #2 |
| treatment deep | #2 |
| hmb primary outcome | #2 |
| thrombophilic defects risk | #2 |
| recurrent deep | #2 |
| pulmonary embolism asthma | #2 |
| nematode anticoagulant | #2 |
| sspe patients patients | #2 |
| recurrent vte risk | #2 |
| mdct reference standard | #2 |
| coagulation factors prolactin | #2 |
| hemorr2hages atria scores | #2 |
| fibrinolysis influenza | #2 |
| received edoxaban | #2 |
| efficiency original score | #2 |
| composite scores area | #2 |
| pharmacological strategies | #2 |
| major clinically | #2 |
| fibrinolytic proteins | #2 |
| 6 months scores | #2 |
| healthcare settings findings | #2 |
| intermediate phenotype vte | #2 |
| common alternative diagnoses | #2 |
| graft occlusion patients | #2 |
| major bleeding recurrent | #2 |
| analysis venous | #2 |
| bleeding rate patients | #2 |
| venous | #2 |
| sustained antithrombotic | #2 |
| venous thrombophlebitis | #2 |
| efficiency strategy | #2 |
| prolactin relation | #2 |
| simplified wells | #2 |
| vte orthopedic surgery | #2 |
| hyperglycemia diagnosis | #2 |
| 17 apixaban | #2 |
| clinically suspected | #2 |
| major bleeding edoxaban | #2 |
| coumarin sensitivity | #2 |
| diagnosis pulmonary | #3 |
| patients 6575 years | #3 |
| gestalt probability | #3 |
| prevalence hemostatic abnormalities | #3 |
| healthy donor fmt | #3 |
| vte low | #3 |
| probability dimer | #3 |
| safely excluded | #3 |
| venous thrombosis travel | #3 |
| einstein patients | #3 |
| dvt primary | #3 |
| lmwh | #3 |
| extensive screening | #3 |
| dvt systematic differences | #3 |
| administration rnapc2 | #3 |
| female hemorrhage humans | #3 |
| venous arterial | #3 |
| crt cancer patients | #3 |
| cohort study employees | #3 |
| venous thrombosis positive | #3 |
| ventilation scan | #3 |
| female humans inhibitors | #3 |
| age annual incidence | #3 |
| pulmonary embolism models | #3 |
| dip placebo | #3 |
| single diagnostic | #3 |
| multiple comorbidities polypharmacy | #3 |
| pulmonary embolism gestalt | #3 |
| dvt hip | #3 |
| time venous thrombosis | #3 |
| venous thromboembolism | #3 |
| primary rule | #3 |
| products follow | #3 |
| hf severity risk | #3 |
| ft4 risk | #3 |
| 12month study period | #3 |
| prevalence avws | #3 |
| therapy venous | #3 |
| 95 wells rule | #3 |
| recurrence thrombophlebitis | #3 |
| standard therapy treatment | #3 |
| outpatient treatment dvt | #3 |
| dose reduction edoxaban | #3 |
| cancer active cancer | #3 |
| alternative diagnoses | #3 |
| pad smokers | #3 |
| platelet agents | #3 |
| failurerate | #3 |
| primary wells rule | #3 |
| tb‐402 | #3 |
| ctnt risk stratification | #3 |
| negative predictive proportion | #3 |
| hokusai‐vte | #3 |
| incidence enoxaparin | #3 |
| fxiaso | #3 |
| lmwh pph | #3 |
| rnapc2 fviia | #3 |
| patients venography | #3 |
| subcutaneous lmwh | #3 |
| users incidence | #3 |
| thombosis | #3 |
| ddimer threshold | #3 |
| hasbled | #3 |
| pulmonary embolism‐related death | #3 |
| endogenous apc | #3 |
| revised geneva efficiency | #3 |
| 3633 patients | #3 |
| introduction mdct | #3 |
| thromboembolism low | #3 |
| venous thrombosis cancer | #3 |
| normal result | #3 |
| subcutaneous fondaparinux | #3 |
| incidence total vte | #3 |
| tinaquant assay | #3 |
| favour lmwh | #3 |
| antithrombin iii concentrate | #3 |
| factors prothrombin | #3 |
| composite stroke | #3 |
| warfarin subgroup | #3 |
| influence heparins | #3 |
| prolactin controls | #3 |
| thrombophlebitis treatment | #3 |
| knee factor | #3 |
| wells rule dvt | #3 |
| heparin heparin | #3 |
| patients wells | #3 |
| intravenous loading dose | #3 |
| diagnosis deep | #3 |
| patients ft4 level | #3 |
| nct00643201 | #3 |
| compensated dic | #3 |
| topic heparin heparin | #3 |
| gestalt 95 | #3 |
| plethysmography impedance | #3 |
| activecontrol | #3 |
| factor viiic | #3 |
| treatment lowmolecularweight heparin | #3 |
| thrombophilic defect | #3 |
| normal ctnt presentation | #3 |
| dvt major | #3 |
| bleeding major | #3 |
| cancer patients ate | #3 |
| iii deficiency | #3 |
| lowmolecularweight heparin placebo | #3 |
| treatment vka | #3 |
| einstein studies | #3 |
| lowmolecularweight humans length | #3 |
| adult patients vte | #3 |
| patients gastrointestinal cancer | #3 |
| idrabiotaparinux | #3 |
| vein thrombosis | #3 |
| combination wells score | #3 |
| safety acenocoumarol | #3 |
| incidental pulmonary embolism | #3 |
| oral hormonal cross | #3 |
| placebo n4 | #3 |
| desogestrelcontaining | #3 |
| selectine | #3 |
| idiopathic venous | #3 |
| 6575 years | #3 |
| vte denmark | #3 |
| inhibition blood coagulation | #3 |
| deep vein | #3 |
| axa activity | #3 |
| dvt einstein | #3 |
| simplified wells specificity | #3 |
| protein thrombophilia | #3 |
| dalteparin difference | #3 |
| vte venous thrombosis | #3 |
| vte 3 | #3 |
| 3month vte incidence | #3 |
| einstein dvt | #3 |
| outpatients dvt | #3 |
| ipe cancer patients | #3 |
| stable acute | #3 |
| studies cus strategies | #3 |
| bleeding 3 | #3 |
| heparins cancer | #3 |
| safely | #3 |
| thiophenes venous | #3 |
| death clinical studies | #3 |
| patients venous | #3 |
| clinical models patients | #3 |
| apc protective | #3 |
| vte major burden | #3 |
| predictable pharmacokinetics | #3 |
| enoxaparin follow | #3 |
| idrabiotaparinux warfarin | #3 |
| mutation venous | #3 |
| patients ultrasonography | #3 |
| ultrasonography strategies | #3 |
| sensitivity compression | #3 |
| approaches primary | #3 |
| travel venous thrombosis | #3 |
| patients incidental vte | #3 |
| cancer randomised trials | #3 |
| 02011 | #3 |
| 20210ga | #3 |
| svt vte | #3 |
| vte performance | #3 |
| pulmonary embolism primary | #3 |
| capillary blood sample | #3 |
| diagnosis pulmonary embolism | #3 |
| baseline values placebo | #3 |
| cdr combination | #3 |
| recombinant hirudin rhir | #3 |
| ddimer assays | #3 |
| outcome venous | #3 |
| venous thromboembolism apixaban | #3 |
| presenting location | #3 |
| 3month incidence | #3 |
| recurrent thromboembolic | #3 |
| cardiac troponine | #3 |
| low probability models | #3 |
| treatment low | #3 |
| “gestalt | #3 |
| treatment vte recurrence | #3 |
| atria hemorr2hages | #3 |
| thromboembolism background | #3 |
| treatment vitamin antagonists | #3 |
| impedance predictive | #3 |
| dimer blood | #3 |
| strategies efficiency | #3 |
| wells rule gestalt | #3 |
| mechanisms heparin | #3 |
| 100 years year | #3 |
| definition perelated death | #3 |
| chemotherapy prophylaxis | #3 |
| monoclonal replacement | #3 |
| proximalvein thrombosis | #3 |
| coagulation influence | #3 |
| cancer patients ipe | #3 |
| efficacy heparin | #3 |
| studies hemorrhage | #3 |
| coagulation air travel | #3 |
| discontinuation ufh | #3 |
| pph lmwh | #3 |
| tfindependent | #3 |
| venous thromboembolism thrombophilia | #3 |
| older children vte | #3 |
| nadroparin placebo | #3 |
| embolism‐related | #3 |
| detection dvt | #3 |
| patients proximalvein thrombosis | #3 |
| safely exclude | #3 |
| patients 6 months | #3 |
| heparin edoxaban | #3 |
| risk vkas | #4 |
| symptomatic deep | #4 |
| venous thromboembolism patients | #4 |
| control anticoagulation | #4 |
| bleeding anticoagulants | #4 |
| dimer assays | #4 |
| edoxaban patients | #4 |
| patients alternative diagnosis | #4 |
| patients primary healthcare | #4 |
| chads2 p0001 | #4 |
| women normal levels | #4 |
| disease vte | #4 |
| fibrin generation test | #4 |
| rule pulmonary | #4 |
| thromboembolism vitamin | #4 |
| predilution postdilution | #4 |
| proximal patients | #4 |
| diagnostic management strategies | #4 |
| clot lysis patients | #4 |
| thrombophilia 95 | #4 |
| 335 patients | #4 |
| patient education treatment | #4 |
| patients crcl 60 | #4 |
| global disease burden | #4 |
| serial impedance plethysmography | #4 |
| vte netherlands | #4 |
| warfarin 3 months | #4 |
| diagnostic management | #4 |
| chinese korean ethnicity | #4 |
| women apc resistance | #4 |
| lowmolecular weight heparins | #4 |
| questionnaires venous | #4 |
| tinaquant | #4 |
| population rivaroxaban | #4 |
| amadeus trial | #4 |
| vka treatment | #4 |
| risk occult cancer | #4 |
| thrombosis uedvt | #4 |
| safety pravastatin | #4 |
| life duration | #4 |
| coagulation endotoxin | #4 |
| recurrent vte months | #4 |
| procoagulant factors | #4 |
| coagulation factors risk | #4 |
| prophylaxis lmwh | #4 |
| vitamin antagonists patients | #4 |
| netherlands pulmonary | #4 |
| daily netilmicin | #4 |
| chemotherapy shr | #4 |
| primary pulmonary embolism | #4 |
| refuted | #4 |
| abdomen relationship | #4 |
| ddimer assay patients | #4 |
| embolism dimer | #4 |
| patients nonpermanent | #4 |
| ageadjusted cutoff patients | #4 |
| lowmolecularweight heparin | #4 |
| thromboembolism factor | #4 |
| patients fondaparinux | #4 |
| sankyo | #4 |
| thrombosis deep | #4 |
| activation fibrinolytic | #4 |
| vte global burden | #4 |
| patients clinically | #4 |
| 3587 | #4 |
| preexisting heparin | #4 |
| impedance plethysmography | #4 |
| vitamin antagonist treatment | #4 |
| lmwhs standard heparin | #4 |
| diagnostic prediction models | #4 |
| clinically relevant bleeding | #4 |
| thromboembolism study | #4 |
| vte global | #4 |
| “reversal | #4 |
| episode venous | #4 |
| 150 microg desogestrel | #4 |
| oral rivaroxaban | #4 |
| pregnancies carriers | #4 |
| patients dimer | #4 |
| chromogenic compounds | #4 |
| thromboembolism arterial | #4 |
| gramnegative bacteria humans | #4 |
| venography patients | #4 |
| probability prospective | #4 |
| patients submassive | #4 |
| embolism roc | #4 |
| global burden vte | #4 |
| noacs cancer patients | #4 |
| leiden carriers | #4 |
| 150 microg levonorgestrel | #4 |
| embolism tomography | #4 |
| patient category | #4 |
| treatment unfractionated heparin | #4 |
| rviia thrombin generation | #4 |
| enoxaparin day | #4 |
| 0651 | #4 |
| estrogen therapy patients | #4 |
| travel thrombosis | #4 |
| vte highincome countries | #4 |
| extended treatment | #4 |
| venous thrombosis levels | #4 |
| cleavage sites apc | #4 |
| patients venous thromboembolism | #4 |
| hyperhomocysteinemic relatives | #4 |
| thromboembolism occurred | #4 |
| point dimer | #4 |
| lmwh cancer patients | #4 |
| serial impedance | #4 |
| dutch orthopedic | #4 |
| arterial thrombotic | #4 |
| levels ft4 | #4 |
| thrombosis air | #4 |
| vitamin antagonists | #4 |
| 35±4 | #4 |
| thrombosis ischemic stroke | #4 |
| series venograms | #4 |
| clot resolution | #4 |
| primary failure rate | #4 |
| rfviia injection | #4 |
| nct00571649 | #4 |
| cancer vwf | #4 |
| total vte | #4 |
| chemotherapy vte prophylaxis | #4 |
| criteria dose reduction | #4 |
| received warfarin | #4 |
| 10172 | #4 |
| vte total | #4 |
| vte treatment patients | #4 |
| enoxaparin female humans | #4 |
| postthrombotic symptoms | #4 |
| diagnosis uedvt | #4 |
| thrombophilic families | #4 |
| measurement abi | #4 |
| advanced cancer 95 | #4 |
| rivaroxaban 20 | #4 |
| disease burden vte | #4 |
| thromboembolism systematic | #4 |
| hemorr2hages | #4 |
| noacs netherlands | #4 |
| lmwh female heparin | #4 |
| 6 months prophylaxis | #4 |
| embolism background | #4 |
| protecht | #4 |
| thrombosis symptomatic | #4 |
| thromboembolism treatment | #4 |
| contraindications treatment | #4 |
| ultrasonography venous | #4 |
| apixaban efficacy | #4 |
| patients edoxaban | #4 |
| idiopathic venous thrombosis | #4 |
| negative point | #4 |
| hemostatic profile | #4 |
| dose noacs | #4 |
| mbe patients | #4 |
| doac studies | #4 |
| death survey | #4 |
| rivaroxaban enoxaparin vka | #5 |
| 8491 | #5 |
| endogenous activated | #5 |
| clinical presentation clinical | #5 |
| factor leiden 95 | #5 |
| coronary angioplasty angioplasty | #5 |
| patients subtherapeutic | #5 |
| bleeding cancer | #5 |
| thrombophlebitis ultrasonography | #5 |
| endotoxin chimpanzees | #5 |
| embolism reproducibility | #5 |
| normal ctpa | #5 |
| thromboembolism studies | #5 |
| secondary dvt | #5 |
| vka patients | #5 |
| heparin compared | #5 |
| dimer combination | #5 |
| diagnostic strategies | #5 |
| vte patients cancer | #5 |
| thrombosis upper | #5 |
| asymptomatic carriers mutation | #5 |
| ventricular dysfunction echocardiography | #5 |
| fh patients cvd | #5 |
| secondary venous thrombosis | #5 |
| 2 rules | #5 |
| low‐molecular‐weight | #5 |
| panwards | #5 |
| treatment acute dvt | #5 |
| sensitivity negative predictive | #5 |
| iii plasminogen | #5 |
| suspected uedvt | #5 |
| deepvein thrombosis | #5 |
| inhibition plasminogen activation | #5 |
| recurrent dvt patients | #5 |
| severe pph women | #5 |
| patients pulmonary embolism | #5 |
| predilution | #5 |
| endotoxin testing | #5 |
| risk prediction scores | #5 |
| lmwh recommended | #5 |
| outcome major | #5 |
| day rivaroxaban | #5 |
| patients recurrent dvt | #5 |
| low molecularweight humans | #5 |
| ft4 level | #5 |
| incidence prognostic significance | #5 |
| isolated calfvein thrombosis | #5 |
| patients superficial thrombophlebitis | #5 |
| cgp 39393 | #5 |
| treatment fondaparinux | #5 |
| adjusted dimer | #5 |
| pulmonary embolism patients | #5 |
| hokusai | #5 |
| thrombosis primary | #5 |
| netilmicin patients | #5 |
| pregnancy pph | #5 |
| women warfarin | #5 |
| previous venous thromboembolism | #5 |
| elevated plasma level | #5 |
| compression ultrasound | #5 |
| preschool contraceptives | #5 |
| thrombosis leg | #5 |
| diagnosis questionnaire | #5 |
| lmwh incidence | #5 |
| specificity thrombophlebitis | #5 |
| fviii families | #5 |
| pad smoking | #5 |
| transfusion blood loss | #5 |
| repeated ultrasonography | #5 |
| clinical probability assessment | #5 |
| thromboembolism idraparinux | #5 |
| hirudin treatment | #5 |
| coc pregnancy | #5 |
| consensus strategy | #5 |
| molecularweight heparin | #5 |
| southern latin america | #5 |
| cdr patients | #5 |
| outpatients hospital | #5 |
| patients wells score | #5 |
| daiichi sankyo | #5 |
| venous thromboembolism studies | #5 |
| dvt prevalence | #5 |
| phlebography plethysmography | #5 |
| efficiency patients | #5 |
| exclusion venous thromboembolism | #5 |
| burden vte | #5 |
| clinical probability | #5 |
| gestalt | #5 |
| upper extremity thrombosis | #5 |
| vte 6 | #5 |
| thromboembolism thrombosis | #5 |
| cancer strategy | #5 |
| fviia rnapc2 | #5 |
| thromboembolism | #5 |
| medea study | #5 |
| patients parenteral anticoagulants | #5 |
| vte factor | #5 |
| antithrombotic drug treatment | #5 |
| 8292 | #5 |
| thrombophilic defects | #6 |
| synthetic pentasaccharides | #6 |
| assay fibrin | #6 |
| amplify | #6 |
| grade 1a ufh | #6 |
| incidence recurrence | #6 |
| elisapositive | #6 |
| edoxaban efficacy | #6 |
| severe antithrombin | #6 |
| patients uedvt | #6 |
| risk increasing levels | #6 |
| svt extension | #6 |
| thrombosis guidelines | #6 |
| 39393 | #6 |
| anticoagulants hemorrhage | #6 |
| c1173 | #6 |
| embolism pulmonary | #6 |
| severe dic | #6 |
| stressinduced hyperglycaemia | #6 |
| oral anticoagulants dabigatran | #6 |
| probability pulmonary | #6 |
| lmwh cancer | #6 |
| anticoagulant treatment | #6 |
| arterial cardiovascular | #6 |
| thromboembolism bleeding | #6 |
| blood coagulation mechanism | #6 |
| 10±4 | #6 |
| recurrent pulmonary | #6 |
| apixaban treatment dose | #6 |
| neoplasms pulmonary embolism | #6 |
| funding bayer | #6 |
| effects ufh | #6 |
| subcutaneous low | #6 |
| leiden | #6 |
| embolism ventricular | #6 |
| proportion cancer patients | #6 |
| dvt trial | #6 |
| patients anticoagulation clinic | #6 |
| women hyperhomocysteinemia | #6 |
| fixeddose regimen | #6 |
| enoxaparin incidence | #6 |
| ultrasonography normal | #6 |
| vka | #6 |
| patients pulmonary angiography | #6 |
| dabigatran etexilate dabigatran | #6 |
| ft4 patients | #6 |
| outcome occurred | #6 |
| patients iohexol | #6 |
| clinically relevant subgroups | #6 |
| combined utility | #6 |
| patients suspected | #6 |
| treatment ufh | #6 |
| efficiency proportion | #6 |
| endotoxininduced activation | #6 |
| fviia inhibition | #6 |
| d‐dimer testing | #6 |
| dalteparin dose | #6 |
| patients tests | #6 |
| patients diagnostic | #6 |
| oral edoxaban | #6 |
| levonorgestrel desogestrel | #6 |
| perioperative blood loss | #6 |
| dimer cut | #6 |
| repeatedly normal | #6 |
| pulmonary embolism presence | #6 |
| anticoagulants female | #6 |
| wells rule | #6 |
| 12month cumulative incidence | #6 |
| antagonists treatment | #6 |
| 393 patients | #6 |
| vte controls | #6 |
| daily gentamicin | #6 |
| cancer primary patients | #6 |
| risk khorana score | #6 |
| selective beta | #6 |
| symptoms intermittent claudication | #6 |
| treatment pulmonary embolism | #6 |
| effects levonorgestrel | #6 |
| prevalence vte | #6 |
| warfarin venous thromboembolism | #6 |
| symptomatic legs | #6 |
| treatment intermittent claudication | #6 |
| patients lowmolecularweight heparin | #6 |
| patients proximal | #6 |
| subjects vte | #6 |
| pembqol questionnaire | #6 |
| conventional therapy treatment | #6 |
| vte cancer | #6 |
| diagnostic workup | #6 |
| venograms | #6 |
| myocardial infarction ctni | #6 |
| endotoxin assays | #6 |
| 049 95 | #6 |
| vte anticoagulant treatment | #6 |
| factor leiden carriers | #6 |
| patients factor mutation | #6 |
| low absolute risk | #6 |
| isolated deficiencies | #6 |
| initial heparin treatment | #6 |
| duration rivaroxaban | #6 |
| simplired dimer | #6 |
| subcutaneous nadroparin | #6 |
| standardized morbidity ratio | #6 |
| lmwh users users | #6 |
| compression stockings patients | #6 |
| rate major bleeding | #6 |
| treatment svt | #6 |
| noncompressibility | #7 |
| major bleeding | #7 |
| major bleeding vkas | #7 |
| diagnosis venous thrombosis | #7 |
| incidence recurrent vte | #7 |
| 680 | #7 |
| embolism prospective | #7 |
| 220 dabigatran | #7 |
| presence cteph | #7 |
| combination ipg | #7 |
| spiral sensitivity | #7 |
| anticoagulant parameters | #7 |
| vitamin antagonists vka | #7 |
| heparin org | #7 |
| antithrombin protein | #7 |
| proportion older patients | #7 |
| ufh treatment | #7 |
| mpc1609 | #7 |
| primary efficacy | #7 |
| thrombophlebitis adolescent | #7 |
| major bleeding rate | #7 |
| tnf injection | #7 |
| lung scan | #7 |
| specific antidotes | #7 |
| relation prolactin levels | #7 |
| administration bsf | #7 |
| statin treatment risk | #7 |
| phenprocoumon polymorphism | #7 |
| nondiagnostic lung scans | #7 |
| vka therapy | #7 |
| prothrombin risk | #7 |
| negative ddimer test | #7 |
| etexilate oral | #7 |
| factor female humans | #7 |
| neoplasms pulmonary | #7 |
| day initial treatment | #7 |
| carriers venous thromboembolism | #7 |
| patients standard heparin | #7 |
| tb402 | #7 |
| stockings control | #7 |
| ottawa score | #7 |
| carriers defects | #7 |
| aspirin combined | #7 |
| dvt ipg | #7 |
| pulmonary embolism sensitivity | #7 |
| blood coagulation humans | #7 |
| negative predictive npv | #7 |
| leg ultrasonography | #7 |
| rivaroxaban 10 | #7 |
| primary dvt | #7 |
| thromboembolism adult | #7 |
| recurrent dvt | #7 |
| unselected women | #7 |
| thromboembolism vte | #7 |
| treatment doac | #7 |
| thromboembolism total | #7 |
| placebo rivaroxaban | #7 |
| protein protein deficiencies | #7 |
| thrombophilia pregnancy loss | #7 |
| diagnostic suspicion | #7 |
| rates edoxaban | #7 |
| general practitioners guideline | #7 |
| venous thrombosis treatment | #7 |
| 597939 | #7 |
| doppler skin | #7 |
| plasma levels ifngamma | #7 |
| silent pulmonary embolism | #7 |
| perelated death | #7 |
| levels factor viii | #7 |
| vte cancer diagnosis | #7 |
| inhibitor apixaban | #7 |
| relation levels | #7 |
| deepvein thrombosis patients | #7 |
| arterial cardiovascular disease | #7 |
| mutations factor viii | #7 |
| coagulation humans | #7 |
| duration treatment | #8 |
| physicians stockings | #8 |
| proximal deep | #8 |
| prevention vte | #8 |
| acute symptomatic vte | #8 |
| leiden prothrombin | #8 |
| aged phlebography | #8 |
| patients symptomatic vte | #8 |
| patients extended anticoagulation | #8 |
| treatment venous thrombosis | #8 |
| oac adherence | #8 |
| point ultrasonography | #8 |
| chemotherapy low risk | #8 |
| normal computed | #8 |
| inherited thrombophilic | #8 |
| homocysteine markers | #8 |
| v617f jak2 | #8 |
| prospective management | #8 |
| levonorgestrelcontaining | #8 |
| proximal deepvein thrombosis | #8 |
| vitamin antagonists vkas | #8 |
| increased fibrinolytic | #8 |
| structured algorithm | #8 |
| products humans | #8 |
| anticoagulants antineoplastic | #8 |
| contrast venography | #8 |
| probability lung | #8 |
| enoxaparin vka | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| administration low | #8 |
| euro55 | #8 |
| 97 95 | #8 |
| anticoagulation unprovoked vte | #8 |
| compression surveys | #8 |
| analysis apixaban | #8 |
| current approach | #8 |
| risks dvt | #8 |
| inr values patients | #8 |
| comorbidity polypharmacy | #8 |
| ageadjusted ddimer cutoff | #8 |
| patients excluded | #8 |
| optimal intensity | #8 |
| apixaban enoxaparin | #8 |
| symptomatic deepvein thrombosis | #8 |
| vka lmwh | #8 |
| 1599 patients | #8 |
| lmwh grade 1a | #8 |
| objectively confirmed | #8 |
| risk employees | #8 |
| agnelli | #8 |
| heparin vitamin antagonists | #8 |
| recurrent vte mb | #8 |
| dimer concentration | #8 |
| arg506 factor | #8 |
| nafronyl | #8 |
| inr determination | #8 |
| 0·2 | #8 |
| vte score | #8 |
| severe preeclampsia patients | #8 |
| years cumulative incidence | #8 |
| pvoct | #8 |
| p0001 hasbled score | #8 |
| overt cancer | #8 |
| oral glucocorticoids risk | #8 |
| unprovoked vte patients | #8 |
| consecutive outpatients | #8 |
| ufh initial treatment | #8 |
| xii deficient | #8 |
| low clinical probability | #8 |
| wells scores | #8 |
| oral apixaban | #8 |
| funding daiichi | #8 |
| deficiency antithrombin | #8 |
| 150 enoxaparin | #8 |
| warfarin hazard ratio | #8 |
| vascular endothelial barrier | #8 |
| initial heparin | #8 |
| cancer pulmonary embolism | #8 |
| carriers fvl | #8 |
| international organisations | #8 |
| thrombosis adolescent | #8 |
| thrombosis prophylaxis | #8 |
| dimer tests | #8 |
| testing rule | #8 |
| bnp ctnt | #8 |
| tests pulmonary | #8 |
| recurrent vte bleeding | #8 |
| persistent risk factors | #8 |
| nondiagnostic scan | #8 |
| fxi aso | #8 |
| discontinuation anticoagulant treatment | #8 |
| occult cancer patients | #8 |
| method enoxaparin | #9 |
| months efficacy | #9 |
| postdilution | #9 |
| oral antithrombins | #9 |
| vte relatives | #9 |
| compression stockings prevention | #9 |
| combination stroke | #9 |
| thromboembolism cancer | #9 |
| male oligosaccharides | #9 |
| cancer cell extravasation | #9 |
| major bleeding treatment | #9 |
| embolism venous | #9 |
| lipoproteina women | #9 |
| hemorr2hages atria | #9 |
| homocysteine women | #9 |
| diagnostic prediction model | #9 |
| factors thrombophlebitis | #9 |
| characteristics severity | #9 |
| cancer factor | #9 |
| thrombosis compared | #9 |
| thrombosis thromboinflammation | #9 |
| prothrombin 20210a | #9 |
| fxa inhibitor | #9 |
| abnormal vaginal | #9 |
| incidence postthrombotic syndrome | #9 |
| bled bleeding | #9 |
| ultrasonogram | #9 |
| enoxaparin factor | #9 |
| carriers factor leiden | #9 |
| patients fxa inhibitors | #9 |
| independent committee | #9 |
| comorbidities polypharmacy | #9 |
| iii concentrate | #9 |
| crcl 60 | #9 |
| lmwh mortality | #9 |
| treatment prophylaxis | #9 |
| anticoagulant pathways | #9 |
| tafi levels | #9 |
| fondaparinux cancer patients | #9 |
| incidental pulmonary | #9 |
| cancer episode | #9 |
| vte rcts | #9 |
| heparin therapy patients | #9 |
| discontinuing anticoagulation | #9 |
| apixaban oral factor | #9 |
| patients active cancer | #9 |
| atiii concentrates | #9 |
| treatment edoxaban | #9 |
| edoxaban major bleeding | #9 |
| placebo plasma levels | #9 |
| concomitant cancer | #9 |
| weight heparin | #9 |
| daiichisankyo | #9 |
| normal ddimer | #9 |
| cofact | #9 |
| therapeutic dose patients | #9 |
| strategies dimer | #9 |
| serotonin platelet | #9 |
| oral contraceptive pregnancy | #9 |
| thrombosis venous thromboembolism | #9 |
| büller | #9 |
| acute medical illnesses | #9 |
| generation pill | #9 |
| longterm treatment vte | #9 |
| diagnosis mdct | #9 |
| nonpermanent | #9 |
| oral administration dabigatran | #10 |
| incidence major bleeding | #10 |
| ddimer concentration | #10 |
| crp test | #10 |
| normohomocysteinemic | #10 |
| rabbits administration | #10 |
| ageadjusted cutoff | #10 |
| incidence 1000 personyears | #10 |
| snp scores | #10 |
| pregnancy carriers | #10 |
| treatment vitamin | #10 |
| schedule heparin | #10 |
| protein dic | #10 |
| single loss | #10 |
| 100 years discontinuation | #10 |
| patients endotoxemia | #10 |
| retrospective study efficacy | #10 |
| deficiencies antithrombin | #10 |
| anticoagulants | #10 |
| gramnegative septicemia | #10 |
| rates recurrent vte | #10 |
| fii mutation | #10 |
| magellan trial | #10 |
| cancer patients vte | #10 |
| inr cases | #10 |
| nadroparine | #10 |
| animal heparin | #10 |
| major bleeding crnmb | #10 |
| treatment uedvt | #10 |
| subcutaneous metaanalysis | #10 |
| wells | #10 |
| intimamedia thickness imt | #10 |
| fondaparinux risk | #10 |
| leg veins | #10 |
| rfviia blood loss | #10 |
| embolism patients | #10 |
| aged antithrombin | #10 |
| cus diagnosis | #10 |
| cvd fh patients | #10 |
| simplified geneva | #10 |
| treatment aprotinin | #10 |
| probability pulmonary embolism | #10 |
| thrombosis background | #10 |
| asymptomatic pulmonary embolism | #10 |
| bled scores | #10 |
| 4470 | #10 |
| vnv | #10 |
| oral thrombin inhibitor | #10 |
| venous thromboembolic event | #10 |
| cancer patients lmwh | #10 |
| vte efficacy | #10 |
| year years | #10 |
| injection avidin | #10 |
| severity clinical | #10 |
| extremity deep | #10 |
| inherited thrombophilic factors | #10 |
| embolism clinical | #10 |
| factor levels patients | #10 |
| thrombophlebitis adult | #10 |
| patients venous thrombosis | #10 |
| lmwh studies | #10 |
| heparin nomogram | #10 |
| dvt lower extremity | #10 |
| 1215 patients | #10 |
| magellan study | #10 |
| hypocoagulable state | #10 |
| thr incidence | #10 |
| induced coagulation | #10 |
| venous thrombosis | #10 |
| 598 patients | #10 |
| factor prevention | #10 |
| patients cancer vte | #11 |
| gps training | #11 |
| endotoxin pentoxifylline | #11 |
| d‐dimer levels | #11 |
| clinical pretest | #11 |
| incidence major | #11 |
| crnmb 95 | #11 |
| intensity anticoagulation | #11 |
| fondaparinux hemorrhage | #11 |
| adult anticoagulants | #11 |
| knee clinical trials | #11 |
| 880 patients | #11 |
| patients probability | #11 |
| reference testing | #11 |
| sulfates dermatan | #11 |
| screening cancer | #11 |
| air travel | #11 |
| cancer patients evidence | #11 |
| previous venous | #11 |
| hospital lmwh | #11 |
| inhibitors hemorrhage | #11 |
| pcc dabigatran | #11 |
| patients cvcs | #11 |
| cancer patients dvt | #11 |
| thromboembolism major | #11 |
| combination dimer | #11 |
| embolism prevalence | #11 |
| dabigatran enoxaparin | #11 |
| embolism recurrence | #11 |
| pulmonary angiography venography | #11 |
| pyridines thiazoles | #11 |
| vte vwf | #11 |
| edoxaban | #11 |
| weight humans | #11 |
| pregnancyrelated complications | #11 |
| org 10172 | #11 |
| lmwh pregnancies | #11 |
| patients anticoagulant treatment | #11 |
| mutations prevalence | #11 |
| variation inr | #11 |
| lmwh pregnancy | #11 |
| carriers factor | #11 |
| 750 μg | #11 |
| 30 microg ethinylestradiol | #11 |
| recombinant human tnf | #11 |
| gentamicin treatment patients | #11 |
| oral dabigatran | #11 |
| endotoxin assay | #11 |
| levels prolactin | #11 |
| pulmonary embolism incidence | #11 |
| heparinoid org | #11 |
| dvt | #11 |
| ldfr | #11 |
| ufh studies | #11 |
| factor venous | #11 |
| haemophilia vwd | #11 |
| medical conferences | #11 |
| deficient women | #12 |
| safety efficiency | #12 |
| bayer schering pharma | #12 |
| annual incidence vte | #12 |
| topic venous | #12 |
| bnp cardiac troponin | #12 |
| risk venous | #12 |
| livebirth rate | #12 |
| stopping anticoagulation | #12 |
| venous thromboembolism incidence | #12 |
| dvt treatment | #12 |
| subsegmental pulmonary emboli | #12 |
| pioped study | #12 |
| outcomes venous thromboembolism | #12 |
| warfarin recurrent vte | #12 |
| outpatient management patients | #12 |
| control metaanalysis | #12 |
| hirulog1 | #12 |
| peghirudin | #12 |
| patients lupus anticoagulant | #12 |
| humanized arthroplasty | #12 |
| recurrent vte anticoagulation | #12 |
| geneva score | #12 |
| doseadjustment | #12 |
| hemodynamically stable | #12 |
| warfarin therapy inr | #12 |
| observation risk | #12 |
| prevention venous thrombosis | #12 |
| female heparin humans | #12 |
| concomitant disorders | #12 |
| patients incidental | #12 |
| event recurrence | #12 |
| proximal veins | #12 |
| fondaparinux unfractionated heparin | #12 |
| months primary | #12 |
| ageadjusted ddimer | #12 |
| anticoagulant factor | #12 |
| factor leiden prothrombin | #12 |
| thrombophilic | #12 |
| 9702 | #12 |
| vte recurrence risk | #12 |
| proximal vein | #12 |
| thrombosis dvt | #12 |
| thrombin generation fibrinolysis | #12 |
| 72 children | #12 |
| paulin | #12 |
| treatment crt | #12 |
| recurrent vte | #12 |
| nephro | #12 |
| 9295 | #12 |
| noacs vka | #12 |
| perelated | #12 |
| women factor | #12 |
| patients lmwhs | #12 |
| crd42013003526 | #12 |
| anticoagulation unprovoked | #12 |
| vka noacs | #12 |
| warfarin treated | #12 |
| levels factor | #13 |
| strain gauge plethysmography | #13 |
| obesity haemophilia patients | #13 |
| randomized cross | #13 |
| prevention venous thromboembolism | #13 |
| vte major | #13 |
| heparin low | #13 |
| association venous thrombosis | #13 |
| dimer threshold | #13 |
| vte groups | #13 |
| bayer healthcare | #13 |
| nct00986154 | #13 |
| thrombosis young | #13 |
| 95 carriers | #13 |
| occult cancer | #13 |
| arterial thromboembolism ate | #13 |
| spiral computed tomography | #13 |
| treatment venous thromboembolism | #13 |
| safety oral | #13 |
| time prothrombin | #13 |
| arixtra | #13 |
| clinical decision rules | #13 |
| pselectin patients | #13 |
| ufh dalteparin | #13 |
| inhibition tnf | #13 |
| continuous intravenous heparin | #13 |
| antithrombin iii activity | #13 |
| patients anticoagulant | #13 |
| patients thrombophilia | #13 |
| dabigatran 220 | #13 |
| selective testing | #13 |
| dvt lower | #13 |
| marder score | #13 |
| factor viii apc | #13 |
| recombinant hirudin rhirudin | #13 |
| concomitant antiplatelet therapy | #13 |
| hematologic pregnancy trimester | #13 |
| factor leiden mutation | #13 |
| rivaroxaban thiophenes | #13 |
| dabigatran vte | #13 |
| daily subcutaneous | #13 |
| inferiority efficacy | #13 |
| thrombosis acute | #13 |
| conventional anticoagulants | #13 |
| uedvt | #13 |
| vte | #13 |
| superficial thrombophlebitis | #13 |
| safety doacs | #13 |
| plethysmograms | #13 |
| 86 percent | #13 |
| major hip | #13 |
| vte female humans | #13 |
| vte recurrence 95 | #13 |
| category studies | #13 |
| indication anticoagulation | #13 |
| plethysmography | #13 |
| groups inr | #13 |
| dimer testing | #13 |
| deepvein thrombosis dvt | #13 |
| bleeding events edoxaban | #13 |
| vte 64 | #13 |
| cadherins endothelium | #14 |
| incidence severe pph | #14 |
| cancer patients anticoagulation | #14 |
| gastrointestinal bleeding patients | #14 |
| riete score | #14 |
| 12 kg1 | #14 |
| thrombophilia patients | #14 |
| treatment duration patients | #14 |
| aged anticoagulants | #14 |
| acute deep | #14 |
| doseranging study | #14 |
| revised geneva | #14 |
| treated lmwh | #14 |
| vte months | #14 |
| limited screening | #14 |
| patients vka therapy | #14 |
| recurrent venous | #14 |
| aged plethysmography | #14 |
| bolus intravenous injection | #14 |
| lmwh vka | #14 |
| pregnancy venous | #14 |
| costs dvt | #14 |
| recurrent venous thromboembolism | #14 |
| female fibrin | #14 |
| plasminogen apoa | #14 |
| experimental endotoxaemia | #14 |
| anticoagulant rivaroxaban | #14 |
| conventionaltherapy | #14 |
| thrombosis | #14 |
| patients dvt | #14 |
| standard heparin | #14 |
| higher ddimer levels | #14 |
| safety edoxaban | #14 |
| fvl carriers | #14 |
| vte statin | #14 |
| aspirin women | #14 |
| crnm | #14 |
| patients acute vte | #14 |
| edoxaban oral factor | #14 |
| factor viii levels | #14 |
| atiii deficiency | #14 |
| patients outpatients | #14 |
| 17 placebo | #14 |
| ultrasound strategies | #14 |
| placebo rfviia | #14 |
| edoxaban warfarin | #14 |
| effects hyperthyroidism | #14 |
| loss women | #14 |
| low molecular | #14 |
| obstetric complications women | #14 |
| awareness pad | #14 |
| thromboembolism age | #14 |
| dvt lower extremities | #14 |
| symptomatic pulmonary | #14 |
| unprovoked vte vte | #14 |
| prophylaxis venous thromboembolism | #15 |
| patients vitamin antagonists | #15 |
| antagonist vka | #15 |
| pregnancy outcome pregnancy | #15 |
| subcutaneous regimen | #15 |
| diagnosis venous | #15 |
| treatment 12 months | #15 |
| generation oral | #15 |
| probability assessment | #15 |
| thrombinography | #15 |
| doacs aspirin | #15 |
| experimental thrombosis | #15 |
| thyroid hormone excess | #15 |
| vitaminkantagonists | #15 |
| inr patient | #15 |
| clinically relevant endpoints | #15 |
| fondaparinux efficacy | #15 |
| recombinant factor viia | #15 |
| arg562 | #15 |
| coagulation | #15 |
| lmwh ufh | #15 |
| established vte | #15 |
| cardiovascular diseases thrombosis | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| primary safety outcome | #15 |
| symptomatic events | #15 |
| abdominal pelvic | #15 |
| subcutaneous enoxaparin | #15 |
| khorana score | #15 |
| patients ctpa | #15 |
| prior venous thromboembolism | #15 |
| edoxaban treatment | #15 |
| studies pulmonary | #15 |
| anticoagulants patients | #15 |
| oral direct factor | #15 |
| control subjects prevalence | #15 |
| coc vte | #15 |
| thrombosis diagnosis | #15 |
| inr range | #15 |
| cteph incidence | #15 |
| lomoparan | #15 |
| activation contact | #15 |
| thrombus growth | #15 |
| enoxaparin vte | #15 |
| arg506 | #15 |
| factor leiden | #15 |
| 500 pg | #15 |
| women unexplained | #16 |
| combination clinical | #16 |
| recurrent symptomatic | #16 |
| thrombosis adult | #16 |
| occult cancer detection | #16 |
| bleeding aged | #16 |
| thrombosis haemostasis | #16 |
| cancer cancer patients | #16 |
| patients acenocoumarol | #16 |
| netilmicin gentamicin | #16 |
| major bleeding anticoagulation | #16 |
| 6 months placebo | #16 |
| analysis rivaroxaban | #16 |
| vterelated death | #16 |
| thrombosis association | #16 |
| cancer screening patients | #16 |
| vte khorana score | #16 |
| warfarin acenocoumarol | #16 |
| abdomino | #16 |
| postthrombotic syndrome children | #16 |
| positivity threshold | #16 |
| venous thrombosis warfarin | #16 |
| subsequent pregnancy loss | #16 |
| factor inhibitor | #16 |
| 100 95 | #16 |
| arterial vascular events | #16 |
| test clinical | #16 |
| viia activity | #16 |
| impaired fibrinolysis | #16 |
| risk clinically | #16 |
| factors major | #16 |
| major bleeding events | #16 |
| dvt lmwh | #16 |
| avws patients | #16 |
| thromboembolism time | #16 |
| thrombosis low | #16 |
| deep venous thrombosis | #16 |
| ddimer levels patients | #16 |
| vkorc1 gene | #17 |
| hematoma heparin | #17 |
| patients overt hypothyroidism | #17 |
| ctscans | #17 |
| gentamicin netilmicin | #17 |
| dimer assay | #17 |
| 12 months patients | #17 |
| dvt prevention | #17 |
| pharmo record linkage | #17 |
| excessive blood loss | #17 |
| lmwhs patients | #17 |
| patients impedance | #17 |
| anticoagulants drug | #17 |
| compared enoxaparin | #17 |
| factor monoclonal | #17 |
| 516 patients | #17 |
| vte edoxaban | #17 |
| fibrinolysis treatment | #17 |
| diagnosis svt | #17 |
| topic hemorrhage humans | #17 |
| recurrent vte events | #17 |
| anticoagulant therapy patients | #17 |
| female humans vte | #17 |
| thrombosis clinical | #17 |
| factors venous | #17 |
| prohemostatic | #17 |
| management crt | #17 |
| scan classification | #17 |
| rivaroxaban oral factor | #17 |
| anticoagulants clinical | #17 |
| women mutation | #17 |
| 2688 | #17 |
| endotoxemia bacteremia | #17 |
| fragment f1 | #17 |
| thromboembolism patients | #17 |
| permanent patients | #17 |
| mutation women | #17 |
| lower specificity | #17 |
| incidence pts | #17 |
| weight adjusted | #18 |
| sanofi aventis | #18 |
| relevant nonmajor | #18 |
| combined form | #18 |
| cancer vte | #18 |
| flight hours | #18 |
| 023 | #18 |
| treatment vkas | #18 |
| thrombosis total | #18 |
| vka edoxaban | #18 |
| annual incidence | #18 |
| simplired | #18 |
| warfarin hazard | #18 |
| thromboembolism venous | #18 |
| hivinfected patients cart | #18 |
| women pregnancy loss | #18 |
| proximal vein thrombosis | #18 |
| stable anticoagulation | #18 |
| edoxaban vte | #18 |
| 4 clinical | #18 |
| vka vte | #18 |
| patients strategy | #18 |
| poc test | #18 |
| venous thromboembolism rivaroxaban | #18 |
| apc thrombin generation | #18 |
| intravenous heparin therapy | #18 |
| aptt heparin | #18 |
| thrombosis pulmonary | #18 |
| favor lmwh | #18 |
| lmwh doacs | #18 |
| prothrombin g20210a | #18 |
| diagnostic strategy | #18 |
| commercial airline pilots | #18 |
| antithrombotic treatment patients | #18 |
| outcome events | #18 |
| coagulation studies | #19 |
| subcutaneous dalteparin | #19 |
| low platelets | #19 |
| 35 women | #19 |
| endogenous fibrinolysis | #19 |
| retropubic prostatectomy | #19 |
| patients prevalence | #19 |
| ddimer tests | #19 |
| versions version | #19 |
| acute recurrent | #19 |
| vwf vte | #19 |
| lmwh patients | #19 |
| increased fibrinolytic activity | #19 |
| active search | #19 |
| antibodynegative | #19 |
| fondaparinux enoxaparin | #19 |
| venous thromboembolism relatives | #19 |
| local angiogenesis | #19 |
| treatment heparin | #19 |
| increased risk relatives | #19 |
| adjusted dose | #19 |
| patients major bleeding | #19 |
| prognostic echocardiography | #19 |
| ipdma | #19 |
| symptomatic dvt | #19 |
| oral dabigatran enoxaparin | #19 |
| abnormal ultrasound | #19 |
| fibrinolytic response | #19 |
| doubleblinding | #19 |
| studies factor | #19 |
| recurrence vte | #19 |
| venography sensitivity | #19 |
| patients sspe | #19 |
| edoxaban dose | #19 |
| recurrent venous thrombosis | #19 |
| systemic activation coagulation | #19 |
| extended oral | #19 |
| patients derivation | #19 |
| objective testing | #19 |
| patients elevated biomarkers | #19 |
| dvt rivaroxaban | #19 |
| 56 95 | #19 |
| vitamin antagonist | #19 |
| ufh lmwh | #19 |
| thromboembolism administration | #19 |
| impedance plethysmography ipg | #20 |
| synthetic cross | #20 |
| abi measurement | #20 |
| therapy rivaroxaban | #20 |
| thrombophilia vte | #20 |
| ctnt bnp | #20 |
| treatment vte | #20 |
| proteins thrombin | #20 |
| shr 95 | #20 |
| standardtherapy hazard ratio | #20 |
| prothrombin mutation | #20 |
| injections subcutaneous | #20 |
| anticoagulation clinic | #20 |
| subsegmental | #20 |
| diagnostic workup patients | #20 |
| single criterion | #20 |
| incidences death | #20 |
| pregnancyrelated vte | #20 |
| symptomatic venous thrombosis | #20 |
| compared ufh | #20 |
| blindly | #20 |
| malignancy time | #20 |
| versions questionnaire | #20 |
| absolute risk | #20 |
| warfarin edoxaban | #20 |
| dabigatran 150 | #20 |
| antagonists vkas | #20 |
| antitpo | #20 |
| life venous thrombosis | #20 |
| carriers prothrombin | #20 |
| guidance ssc | #20 |
| excluded patients | #20 |
| nadroparin | #20 |
| patients ddimer testing | #20 |
| abi risk factors | #20 |
| statin vte | #20 |
| new agent | #20 |
| calf veins | #20 |
| residual venous | #20 |
| risk thrombophilia | #20 |
| thrombosis ultrasonography | #20 |
| intravenous injections | #20 |
| recurrence bleeding | #20 |
| established atherosclerosis | #20 |
| distance treatment | #20 |
| portola | #20 |
| cancer severity | #20 |
| control situation | #20 |
| disease ischemic | #21 |
| hemostatic abnormalities | #21 |
| thrombosis anticoagulants | #21 |
| doacs lmwhs | #21 |
| distance quality | #21 |
| risk cohort study | #21 |
| treatment apixaban | #21 |
| thromb | #21 |
| outcome incidence | #21 |
| major bleeding patients | #21 |
| fibrinolysis inflammation | #21 |
| treatment acenocoumarol | #21 |
| d‐dimer | #21 |
| deep venous | #21 |
| internists cardiologists | #21 |
| carriers noncarriers | #21 |
| patients 3 months | #21 |
| concomitant anti | #21 |
| hemodynamically stable patients | #21 |
| venogram | #21 |
| vte patients | #21 |
| prothrombin 20210 | #21 |
| discriminatory performance | #21 |
| ddimer concentrations | #21 |
| occult malignancy | #21 |
| current standard treatment | #21 |
| dose subcutaneous | #22 |
| anticoagulants heparin | #22 |
| hormonal cross | #22 |
| patients recurrent symptoms | #22 |
| ttr inr | #22 |
| bleeding treatment | #22 |
| vascular endotoxins | #22 |
| treatment dvt | #22 |
| public awareness | #22 |
| thrombophilia screening | #22 |
| anticoagulants humans | #22 |
| dimer age | #22 |
| patientyears | #22 |
| cttr | #22 |
| host defense response | #22 |
| lpa plasminogen | #22 |
| patients immobilization | #22 |
| acute vte | #22 |
| doppler venous thrombosis | #22 |
| daily enoxaparin | #22 |
| alternative anticoagulation | #22 |
| patients severe hf | #22 |
| riskbenefit ratio | #22 |
| venous thromboembolic | #22 |
| cmax ctrough | #22 |
| recurrent thromboembolism | #22 |
| dichotomously | #22 |
| safety treatment | #22 |
| time inr | #22 |
| hasbled score | #23 |
| enoxaparin 40 | #23 |
| development dic | #23 |
| direct factor inhibitors | #23 |
| rivaroxaban dosing | #23 |
| cancer patients risk | #23 |
| ambulatory cancer patients | #23 |
| recurrence venous | #23 |
| odis | #23 |
| n1157 | #23 |
| fondaparinux | #23 |
| standardduration | #23 |
| venous arterial thrombosis | #23 |
| prevalence venous thromboembolism | #23 |
| patients coagulation disorders | #23 |
| normal angiogram | #23 |
| vte studies | #23 |
| gentamicin patients | #23 |
| thromboembolism anticoagulants | #23 |
| elevated ctni | #23 |
| 5392 | #23 |
| bidirectional relation | #23 |
| life pulmonary embolism | #23 |
| lower extremity amputation | #23 |
| 2 investigators | #23 |
| time platelet | #23 |
| percentage increase | #23 |
| kakkar | #23 |
| 011 | #23 |
| clotbound thrombin | #23 |
| followup incidence | #24 |
| presence dvt | #24 |
| viiic | #24 |
| therapy heparin | #24 |
| patients severe bleeding | #24 |
| prevalence deficiencies | #24 |
| predefined criteria | #24 |
| subtherapeutic | #24 |
| safety fondaparinux | #24 |
| patients acute treatment | #24 |
| independent external validation | #24 |
| specific antidote | #24 |
| patients abnormal perfusion | #24 |
| years episode | #24 |
| a21gly | #24 |
| thrombosis carriers | #24 |
| recurrent thromboembolism patients | #24 |
| ddimer testing | #24 |
| rates venous thromboembolism | #24 |
| levels fviii | #24 |
| food drugs | #24 |
| desogestrel levonorgestrel | #24 |
| 049 | #24 |
| ufh patients | #24 |
| fondaparinux placebo | #24 |
| parameters fibrinolysis | #24 |
| month incidence | #24 |
| bleeding complication | #24 |
| recurrent pulmonary embolism | #24 |
| lowmolecularweight humans | #24 |
| overt hyperthyroidism | #24 |
| factors anticoagulants | #25 |
| fibrinogen degradation | #25 |
| xii activity | #25 |
| vte clinical | #25 |
| expert radiologists | #25 |
| treatment symptomatic | #25 |
| sepsis intravascular coagulation | #25 |
| anatomical extent | #25 |
| specificity efficiency | #25 |
| studies lmwh | #25 |
| f1 2 levels | #25 |
| amadeus | #25 |
| cha2ds2vasc chads2 | #25 |
| thromboembolism acute | #25 |
| willebrand factor adamts13 | #25 |
| lmwh treatment | #25 |
| fatima | #25 |
| patients gastrointestinal bleeding | #25 |
| middeldorp | #25 |
| perfusion lung scan | #25 |
| influence smoking | #25 |
| suggestions improvement | #25 |
| patients cdr | #26 |
| parameters risk | #26 |
| ecq | #26 |
| venous thromboemboli | #26 |
| 9715 | #26 |
| doacs vitamin antagonists | #26 |
| dalteparin ufh | #26 |
| patients symptomatic dvt | #26 |
| major bleeding bleeding | #26 |
| events year | #26 |
| homozygous carriers | #26 |
| specificity negative predictive | #26 |
| rate recurrent vte | #26 |
| unprovoked vte | #26 |
| failure rate | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| edoxaban versus | #26 |
| miscarriage stillbirth | #26 |
| edoxaban vka | #26 |
| asymptomatic carriers | #26 |
| treatment lmwh | #26 |
| hormonal manipulation | #26 |
| rethoracotomy | #26 |
| viia complex | #26 |
| patients essential thrombocythaemia | #26 |
| perfusion lung | #27 |
| treating physician | #27 |
| current guidance | #27 |
| vte doacs | #27 |
| enoxaparin female | #27 |
| lowmolecularweight heparin patients | #27 |
| thrombosis venous | #27 |
| nonmajor | #27 |
| noncarriers 95 | #27 |
| patients major hemorrhage | #27 |
| lmwh prophylaxis | #27 |
| vte thr | #27 |
| extremity venous | #27 |
| 0·63 | #27 |
| thrombocytopenia antibodies | #27 |
| npv patients | #27 |
| day 35 | #27 |
| months studies | #27 |
| anticoagulants factor | #27 |
| low molecularweight heparin | #27 |
| thrombophlebitis | #27 |
| anticoagulants blood | #27 |
| unprovoked venous | #27 |
| cancer spread | #27 |
| patients 50 | #27 |
| female heterozygote | #27 |
| patients elevated levels | #27 |
| combined training | #27 |
| training gps | #27 |
| venous thromboembolism carriers | #27 |
| airline pilots | #27 |
| apc plasma | #28 |
| cancer venous thromboembolism | #28 |
| unexplained | #28 |
| presentation followup | #28 |
| vte 6 months | #28 |
| tests diagnostic | #28 |
| therapeutic doses | #28 |
| factors recurrent | #28 |
| pph severe pph | #28 |
| hirudin therapy | #28 |
| anticoagulants compared | #28 |
| patients unprovoked | #28 |
| anticoagulation women | #28 |
| pembqol | #28 |
| coagulation tissue factor | #28 |
| monitoring therapy | #28 |
| receiving rivaroxaban | #28 |
| embolism retrospective | #28 |
| acutely medical patients | #28 |
| vitamin aged | #28 |
| rfviia placebo | #28 |
| 2½ | #28 |
| objective tests | #28 |
| 4650 | #28 |
| specific reversal agent | #28 |
| pulmonary angiography | #29 |
| spread cancer | #29 |
| prediction scores | #29 |
| 8240 | #29 |
| pulmonary embolism recurrence | #29 |
| thrombosis 95 | #29 |
| direct oral anticoagulants | #29 |
| g20210a mutation | #29 |
| authors incidence | #29 |
| dabigatran pcc | #29 |
| aged morpholines | #29 |
| current management strategies | #29 |
| oral glucocorticoids | #29 |
| pulmonary embolism death | #29 |
| dutch famine | #29 |
| septicemia | #29 |
| recurrence svt | #29 |
| aminoglycoside therapy | #29 |
| plateletactivating antibodies | #29 |
| aspirin placebo | #29 |
| sex‐specific differences | #29 |
| cindexes | #29 |
| dvt pulmonary embolism | #29 |
| 1000 individuals | #29 |
| diagnosis dvt | #29 |
| patients standard therapy | #29 |
| acenocoumarol patients | #29 |
| patients avws | #29 |
| blind trials | #29 |
| bleeding increased | #29 |
| heparin versus | #29 |
| major bleeding rivaroxaban | #29 |
| thrombo | #29 |
| resistance activated protein | #29 |
| pbac score | #29 |
| years year | #29 |
| thrombosis treatment | #29 |
| residual thrombosis | #30 |
| new anticoagulants | #30 |
| prevention venous | #30 |
| 95 risk | #30 |
| administration pentoxifylline | #30 |
| thromboembolism warfarin | #30 |
| rule patients | #30 |
| costs diagnosis | #30 |
| embolism risk | #30 |
| direct oral factor | #30 |
| doac vka | #30 |
| 1000 personyears incidence | #30 |
| ufh vte | #30 |
| markers coagulation activation | #30 |
| cancer venous | #30 |
| subcutaneous heparin | #30 |
| support techniques | #30 |
| patients vte | #30 |
| f1 2 | #30 |
| xii factor | #30 |
| vte coc | #30 |
| standardtherapy | #31 |
| recurrent episode | #31 |
| experimental endotoxemia | #31 |
| inhibitor edoxaban | #31 |
| 8755 | #31 |
| pharmacological prophylaxis | #31 |
| recurrent vte patients | #31 |
| thromboprophylaxis risk | #31 |
| women recurrent miscarriage | #31 |
| ventilation scintigraphy | #31 |
| apixaban placebo | #31 |
| 2 antiplasmin | #31 |
| incidence pph | #31 |
| rfviia novoseven | #31 |
| activation blood coagulation | #31 |
| dimer cutoff | #31 |
| placebo observation | #31 |
| analysis reviewers | #31 |
| patients deepvein thrombosis | #31 |
| thromboembolism adolescent | #31 |
| extended prophylaxis | #31 |
| rhir | #31 |
| prevalence probability | #31 |
| term risk | #31 |
| vte ufh | #31 |
| 0206 | #31 |
| recurrent patients | #31 |
| antithrombotic therapies | #31 |
| ufh fondaparinux | #31 |
| events 95 | #31 |
| incidence cteph | #31 |
| iii activity | #31 |
| dvt pulmonary | #31 |
| bled | #31 |
| imaging sensitivity specificity | #31 |
| factors thrombolytic | #32 |
| parenteral anticoagulation | #32 |
| factor female | #32 |
| leiden mutation | #32 |
| netherlands predictive | #32 |
| treatment anticoagulants | #32 |
| suspected patients | #32 |
| varicosis | #32 |
| resistance activated | #32 |
| normal genotype | #32 |
| year 95 | #32 |
| ufh | #32 |
| age adjusted | #32 |
| negative septicemia | #32 |
| khorana score patients | #32 |
| international society thrombosis | #32 |
| parenteral anticoagulants | #32 |
| negative dimer | #32 |
| warfarin vte | #32 |
| low clinical | #32 |
| generation patients | #32 |
| thromboembolism young | #33 |
| rhirudin | #33 |
| heparin lmwh | #33 |
| activation factors | #33 |
| prophylaxis vte | #33 |
| active implementation | #33 |
| warfarin risks | #33 |
| factor viii patients | #33 |
| chapter patients | #33 |
| mega study | #33 |
| anticoagulant protein | #33 |
| apixaban treatment | #33 |
| pulmonary angiogram | #33 |
| additional tests | #33 |
| low probability | #33 |
| unitage | #33 |
| subcutaneous male | #33 |
| nephrotoxicity gentamicin | #33 |
| cancer patients diagnosis | #33 |
| data meta | #33 |
| vte thrombophilia | #34 |
| phytonadione | #34 |
| compare efficacy | #34 |
| pregnancy loss women | #34 |
| warfarin adult | #34 |
| lmwh unfractionated heparin | #34 |
| 9241 | #34 |
| 590 | #34 |
| grade 1a | #34 |
| plasmin alpha | #34 |
| control trials | #34 |
| subsegmental pulmonary embolism | #34 |
| hemorrhage heparin humans | #34 |
| vte compared | #34 |
| apcsr | #34 |
| bilateral venography | #34 |
| 10 95 | #34 |
| 3 months treatment | #34 |
| reocclusion patients | #34 |
| anticoagulant | #34 |
| thrombosis lower | #34 |
| deficiency protein | #34 |
| patients efficiency | #35 |
| rviia | #35 |
| embolism | #35 |
| prevention model | #35 |
| activation coagulation | #35 |
| weekly subcutaneous | #35 |
| risk members | #35 |
| surgery hip | #35 |
| enoxaparin prevention | #35 |
| radiologists diagnosis | #35 |
| anticoagulants benzimidazoles | #35 |
| neoplasms venous | #35 |
| 36 95 | #35 |
| statin association | #35 |
| pph blood loss | #35 |
| lung scanning | #35 |
| novoseven | #36 |
| catheterrelated infection | #36 |
| venous thromboembolism dabigatran | #36 |
| fibrinogen depletion | #36 |
| 4139 | #36 |
| viii levels | #36 |
| venous thromboembolic disease | #36 |
| levels coagulation | #36 |
| thrombophilia venous | #36 |
| iii antithrombin | #36 |
| 287 patients | #36 |
| acute symptomatic | #36 |
| regular monitoring | #36 |
| riskbenefit | #36 |
| hellp patients | #36 |
| 1698 | #36 |
| fibrinolytic activation | #36 |
| studies echocardiography | #36 |
| inherited risk factors | #36 |
| factors travel | #36 |
| peripheral endovascular | #36 |
| dose reduction patients | #36 |
| treatment acute vte | #36 |
| outcome composite | #37 |
| factors thrombophilia | #37 |
| thrombosis humans | #37 |
| screening occult | #37 |
| vte increased | #37 |
| tat complexes | #37 |
| cumulative incidence vte | #37 |
| ctpa patients | #37 |
| anticoagulants prevention | #37 |
| prophylactic heparin | #37 |
| suspected venous | #37 |
| risk factors pts | #37 |
| warfarin 95 | #37 |
| magellan | #37 |
| bagsvaerd | #37 |
| lwmh | #37 |
| pad studies | #37 |
| recombinant hirudin | #37 |
| perelated mortality | #37 |
| venography | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| risk venous thrombosis | #37 |
| ototoxicity nephrotoxicity | #37 |
| excluding | #37 |
| anticoagulant action | #37 |
| genotype 95 | #37 |
| rivaroxaban placebo | #38 |
| congenital deficiencies | #38 |
| catheterrelated thrombosis | #38 |
| 10 total | #38 |
| submassive pulmonary | #38 |
| vte bleeding | #38 |
| vte cancer patients | #38 |
| coagulation protein | #38 |
| recurrence day | #38 |
| sensitivity biomarkers | #38 |
| patients ddimer levels | #38 |
| restenosis reocclusion | #38 |
| 2835 | #38 |
| nonmajor bleeding | #38 |
| doac lmwh | #38 |
| age recurrence | #38 |
| 3306 | #38 |
| fetal loss women | #38 |
| anticoagulants female humans | #38 |
| incidence cancer | #39 |
| heparins lmwhs | #39 |
| superficial vein thrombosis | #39 |
| fibrin fibrinogen | #39 |
| diagnostic prediction | #39 |
| enoxaparin placebo | #39 |
| specificity patients | #39 |
| submassive | #39 |
| incidence patients | #39 |
| low molecular weight | #39 |
| compression stocking | #39 |
| 277 patients | #39 |
| time compression | #39 |
| doacs | #39 |
| children familial hypercholesterolemia | #39 |
| systemic inflammatory responses | #39 |
| septic syndrome | #39 |
| continued treatment | #39 |
| embolus | #39 |
| subcutaneous intention | #39 |
| arterial vascular | #40 |
| grade 1a patients | #40 |
| tfmp | #40 |
| bleeding | #40 |
| clotting activation | #40 |
| activatable fibrinolysis | #40 |
| anticoagulant therapy | #40 |
| ambulatory cancer | #40 |
| pemb | #40 |
| anticoagulation therapy patients | #40 |
| standardized definition | #40 |
| day 6 months | #40 |
| therapeutic dosages | #40 |
| episode venous thromboembolism | #40 |
| patients normal | #40 |
| thrombinantithrombin complexes | #40 |
| international clinical | #40 |
| endotoxininduced | #40 |
| dalteparin treatment | #40 |
| fviiic | #40 |
| common femoral vein | #40 |
| heparin therapy | #41 |
| pentasaccharides | #41 |
| cancer lmwh | #41 |
| submassive pulmonary embolism | #41 |
| 7268 | #41 |
| risk recurrent vte | #41 |
| dabigatran etexilate | #41 |
| calf vein thrombosis | #41 |
| endotoxin induced | #41 |
| triage tests | #41 |
| placebo 6 months | #41 |
| anticoagulated patients | #41 |
| lung scintigraphy | #41 |
| 95 genotype | #41 |
| lowmolecularweight heparins | #41 |
| type graft | #42 |
| patients silent | #42 |
| patients vasopressors | #42 |
| stroke thrombosis | #42 |
| 8101 | #42 |
| standardization committee | #42 |
| patients prospective | #42 |
| neoplasms thrombosis | #42 |
| anticoagulation risk | #42 |
| prophylaxis venous | #42 |
| cell extravasation | #42 |
| thrombosis administration | #42 |
| netilmicin | #42 |
| major contributor | #42 |
| ischemic events | #43 |
| draft document | #43 |
| cancer adjusted | #43 |
| 543 patients | #43 |
| probability patients | #43 |
| heparin risk | #43 |
| vkas patients | #43 |
| patients vte risk | #43 |
| venous thrombosis thrombophilia | #43 |
| monthly incidence | #43 |
| post‐thrombotic syndrome | #43 |
| fetal loss | #43 |
| warfarin anticoagulants | #43 |
| initial treatment | #43 |
| venous thromboembolism vte | #43 |
| rtap | #43 |
| experimental venous thrombosis | #44 |
| recurrent vte 95 | #44 |
| nonvka oral anticoagulants | #44 |
| mild hyperhomocysteinaemia | #44 |
| restoration euthyroidism | #44 |
| expert physicians | #44 |
| edoxaban therapy | #44 |
| 10–14 | #44 |
| rate venous | #44 |
| enoxaparin risk | #44 |
| patients tinzaparin | #44 |
| factors thromboembolism | #44 |
| indications patients | #44 |
| efficiency models | #44 |
| role coagulation | #44 |
| protein sepsis | #44 |
| uedvt patients | #44 |
| 95 pulmonary embolism | #44 |
| 20 30 | #44 |
| dose adjusted | #45 |
| patients bnp | #45 |
| coumarin therapy | #45 |
| coagulation activation | #45 |
| treated warfarin | #45 |
| years algorithm | #45 |
| fondaparinux patients | #45 |
| dvt patients | #45 |
| 95 warfarin | #45 |
| wells score | #45 |
| oral direct | #45 |
| revascularisation procedures | #45 |
| venous thrombotic | #45 |
| dose lmwh | #45 |
| daily rivaroxaban | #46 |
| major bleeding placebo | #46 |
| abtpo | #46 |
| stroke risk assessment | #46 |
| healthcare settings | #46 |
| patients unprovoked vte | #46 |
| day levels | #46 |
| ruling | #46 |
| prothrombin fragment f1 | #46 |
| management venous | #46 |
| bleeding rivaroxaban | #46 |
| pioped | #46 |
| extended duration | #46 |
| hospital outpatients | #46 |
| treatment model | #46 |
| ssc isth | #46 |
| standard therapy | #46 |
| percent confidence | #46 |
| boehringer ingelheim | #47 |
| roccurve | #47 |
| central venous lines | #47 |
| bristol myers squibb | #47 |
| male methimazole | #47 |
| episode vte | #47 |
| mutation pregnancy | #47 |
| outcome vitamin | #47 |
| iiia receptors | #47 |
| new oral anticoagulant | #47 |
| ambulatory anticoagulants | #47 |
| mechanical prophylaxis | #47 |
| plasma ddimer levels | #47 |
| factors rivaroxaban | #48 |
| fondaparinux heparin | #48 |
| rivaroxaban compared | #48 |
| elevated plasma levels | #48 |
| recurrence venous thromboembolism | #48 |
| subcommittee | #48 |
| patients pulmonary | #48 |
| diagnosis physicians | #48 |
| daiichi | #48 |
| patients acute dvt | #48 |
| intermediate risk risk | #48 |
| travel risk | #48 |
| thromboprophylactic | #48 |
| thrombotic burden | #48 |
| risk recurrent | #48 |
| small studies | #48 |
| enoxaparin | #49 |
| rivaroxaban prevention | #49 |
| women aspirin | #49 |
| levels protein | #49 |
| factor viii deficiency | #49 |
| lowmolecularweight heparin lmwh | #49 |
| calf vein | #49 |
| vte diagnosis | #49 |
| prospective diagnostic | #50 |
| atria patients | #50 |
| incidence venous thromboembolism | #50 |
| etexilate | #50 |
| buller | #50 |
| transient risk factor | #50 |
| thromboembolism aged | #50 |
| cardiac surgery mortality | #50 |
| treatment threshold | #50 |
| outpatient therapy | #50 |
| dvt diagnosis | #50 |
| vitamink antagonists | #50 |
| intensity treatment | #50 |
| acute respiratory insufficiency | #50 |
| nonselective betablockers | #50 |
| normal perfusion | #51 |
| tomography pulmonary | #51 |
| factor vte | #51 |
| 95 apixaban | #51 |
| strategies treatment | #51 |
| effects coagulation | #51 |
| global disease | #51 |
| patients 11 | #51 |
| previous survey | #51 |
| acenocoumarol | #51 |
| discrimination model | #51 |
| protein deficiencies | #51 |
| doacs vka | #52 |
| pdvt | #52 |
| 1·12 | #52 |
| inhibitors heparin | #52 |
| risk venous thromboembolism | #52 |
| apixaban vte | #52 |
| unnecessarily | #52 |
| patients comorbid conditions | #52 |
| svt patients | #52 |
| lmwh fondaparinux | #52 |
| free thyroxine ft4 | #52 |
| 3 month | #52 |
| vte major bleeding | #52 |
| hematologic malignancies patients | #52 |
| lung scans | #52 |
| postthrombotic syndrome | #53 |
| versus enoxaparin | #53 |
| patients initially | #53 |
| warfarintreated patients | #53 |
| cross study | #53 |
| 40 daily | #53 |
| thromboembolism prevention | #53 |
| thrombophilic factors | #53 |
| suspected venous thromboembolism | #53 |
| 1522 | #53 |
| preference patients | #53 |
| absolute risks | #53 |
| hemostatic balance | #53 |
| 479 patients | #53 |
| reported incidence | #53 |
| major bleeds | #54 |
| 2537 | #54 |
| patients incidence | #54 |
| antithrombotic drug | #54 |
| pai1 levels patients | #54 |
| chads2 cha2ds2vasc | #54 |
| acquired risk factors | #54 |
| prethrombotic | #54 |
| endocrine disorders | #54 |
| male pulmonary embolism | #54 |
| vte mortality | #54 |
| 378 patients | #54 |
| thromboembolism death | #54 |
| 034 | #54 |
| familial thrombophilia | #54 |
| bled score | #54 |
| patients obese | #54 |
| legs patients | #55 |
| long term risk | #55 |
| insurances | #55 |
| nondeficient | #55 |
| proximal extent | #55 |
| methods randomized | #55 |
| compared lmwh | #55 |
| unfractionated heparin | #55 |
| dosereduction | #55 |
| unfractionated heparin ufh | #55 |
| treatment thresholds | #55 |
| anticoagulants arthroplasty replacement | #55 |
| rivaroxaban | #55 |
| biological pan | #55 |
| risk major bleeding | #56 |
| weight heparins | #56 |
| vasopressors | #56 |
| preeclampsia hellp syndrome | #56 |
| tromboembólica | #56 |
| time event | #56 |
| enoxaparin rivaroxaban | #56 |
| level mortality | #56 |
| venous outflow obstruction | #56 |
| vte death | #56 |
| vitamin warfarin | #56 |
| 20210a | #56 |
| major bleeding apixaban | #56 |
| enoxaparin patients | #56 |
| inr values | #56 |
| deficiency prevalence | #56 |
| physicians guidelines | #56 |
| reduced capacity | #56 |
| seventh accp conference | #56 |
| inhibitors female humans | #57 |
| calf dvt | #57 |
| subsegmental pulmonary | #57 |
| ctscan | #57 |
| clinical models | #57 |
| levels survival | #57 |
| antithrombin iii heparin | #57 |
| risk factors vte | #57 |
| lowmolecular weight heparin | #58 |
| unfractionated heparin patients | #58 |
| doacs patients | #58 |
| spiral computed | #58 |
| pharmo | #58 |
| fibrinolysis humans | #58 |
| inhibitors female | #58 |
| malignancy mortality | #58 |
| ruled | #58 |
| thrombin activatable | #58 |
| factor generation | #59 |
| acute venous thromboembolism | #59 |
| aventis | #59 |
| risk factors sensitivity | #59 |
| thrombosis aged | #59 |
| bias trial | #59 |
| heterozygous factor | #59 |
| clot lysis time | #59 |
| mutation prothrombin | #59 |
| risk periods | #59 |
| warfarin treatment | #59 |
| risk vte | #59 |
| safety warfarin | #59 |
| direct oral | #59 |
| incidence symptomatic | #59 |
| atrial fibrillation metaanalysis | #60 |
| fixeddose | #60 |
| 079 95 | #60 |
| pulmonary embolism 95 | #60 |
| anticoagulants treatment | #60 |
| pediatric venous thromboembolism | #60 |
| acute pulmonary embolism | #60 |
| prevalence pulmonary | #60 |
| hemorrhage humans | #60 |
| awareness risk factors | #60 |
| target inr | #60 |
| constans | #60 |
| women difference | #60 |
| hypocoagulable | #61 |
| long‐term treatment | #61 |
| rosendaal | #61 |
| month surgery | #61 |
| free thyroxine | #61 |
| benzimidazoles dabigatran | #61 |
| perfusion ventilation | #61 |
| dvt 95 | #61 |
| 3633 | #61 |
| tests prevalence | #61 |
| cdr score | #61 |
| association protein | #61 |
| amuse | #61 |
| post thrombotic | #62 |
| human endotoxemia | #62 |
| general practitioners patients | #62 |
| 250 patients | #62 |
| combined contraceptives oral | #62 |
| 273 patients | #62 |
| informatizado | #62 |
| activated partial | #62 |
| procoagulant state | #62 |
| protein fibrinogen | #62 |
| ttr patients | #62 |
| patients administration | #62 |
| revised geneva score | #63 |
| treatment network | #63 |
| injection endotoxin | #63 |
| common odds ratio | #63 |
| quantitative test | #63 |
| rivaroxaban lmwh | #63 |
| physicians predictive | #63 |
| venous thromboembolisms | #63 |
| cvrs | #63 |
| factor leiden risk | #63 |
| symptoms dvt | #63 |
| management anticoagulation | #63 |
| women mutations | #63 |
| smoking smoking cessation | #63 |
| 33 women | #63 |
| vte thromboprophylaxis | #63 |
| postthrombotic | #64 |
| thrombophilic risk | #64 |
| bleeding events patients | #64 |
| decision rules | #64 |
| blinded trial | #64 |
| patients aortic valve | #64 |
| cancer noncancer patients | #64 |
| dvts | #64 |
| acute pulmonary | #64 |
| selfadjustment | #64 |
| superficial vein | #64 |
| heparin fondaparinux | #64 |
| oral thrombin | #64 |
| prior vte | #64 |
| vkas treatment | #64 |
| factor inhibitors | #64 |
| accuracy diagnostic tests | #65 |
| treatment pad | #65 |
| ultrasonograms | #65 |
| fvl vte | #65 |
| prothrombin g20210a mutation | #65 |
| prevalence abnormalities | #65 |
| stroke thromboembolism | #65 |
| elfa | #66 |
| 95 bleeding | #66 |
| rapid triage | #66 |
| female heparin | #66 |
| death classification | #66 |
| risk factor thrombosis | #66 |
| dvt sensitivity | #66 |
| axa | #66 |
| 0 points | #66 |
| newer anticoagulants | #66 |
| statin therapy risk | #66 |
| patients factor | #67 |
| atrial fibrillation stroke | #67 |
| rate major | #67 |
| standard therapy patients | #67 |
| 1127 | #67 |
| apixaban | #67 |
| patients tertiles | #67 |
| 1894 | #68 |
| patients benefits | #68 |
| coagulation fibrinolysis | #68 |
| academic medical centre | #68 |
| 3594 | #68 |
| ranging study | #68 |
| 05 95 | #68 |
| fibrinolytic | #68 |
| perioperative blood | #68 |
| 20210g | #68 |
| patients bnp levels | #68 |
| ionis | #69 |
| thrombosis blood | #69 |
| recurrent thrombosis patients | #69 |
| certoparin | #69 |
| justify | #69 |
| postphlebitic | #69 |
| heparin ufh | #69 |
| enfermedad tromboembólica | #69 |
| plasma interleukin | #69 |
| suspected | #69 |
| major bleeding complications | #70 |
| 8190 | #70 |
| mantelhaenszel | #70 |
| gramnegative sepsis | #70 |
| α2ap | #70 |
| thrombosis recurrence | #70 |
| withhold | #70 |
| test patients | #70 |
| fixed dose | #70 |
| rivaroxaban treatment | #70 |
| patients protein | #70 |
| aged predictive | #70 |
| vwfrco | #70 |
| elevated cardiac | #70 |
| cutoff levels | #70 |
| ischemic events patients | #70 |
| diagnostic sensitivity specificity | #71 |
| unfractionated | #71 |
| asymptomatic atherosclerosis | #71 |
| tests prospective | #71 |
| topic costs | #71 |
| thromboprophylaxis | #71 |
| vte vka | #71 |
| levels vwf | #71 |
| clopidogrel placebo | #71 |
| plasminogen plg | #71 |
| hf studies | #72 |
| trifurcation | #72 |
| overt hypothyroidism | #72 |
| viia factor | #72 |
| ddimer values | #72 |
| new anticoagulant | #72 |
| activation prothrombin | #72 |
| elevated factor | #72 |
| patients lmwh | #72 |
| antithrombin iii iii | #72 |
| complications hematologic | #72 |
| versus vitamin | #72 |
| pooled rate | #72 |
| reversal agent | #73 |
| tomography spiral | #73 |
| noacs | #73 |
| prolongations | #73 |
| analysis diagnostic | #73 |
| ddimer measurement | #73 |
| ingelheim | #73 |
| soluble fibrin | #73 |
| 12 months 95 | #73 |
| carriers | #74 |
| female hemorrhage | #74 |
| dvt study | #74 |
| proteins patients | #74 |
| 2550 | #74 |
| 1732 | #74 |
| study selection | #74 |
| 2124 | #74 |
| 5395 | #74 |
| prethrombotic state | #74 |
| experimental metastasis | #74 |
| soluble thrombomodulin | #74 |
| longterm risk | #74 |
| suspected dvt | #74 |
| selective factor | #75 |
| carotid femoral arteries | #75 |
| thrombolytic therapy patients | #75 |
| postoperative dvt | #75 |
| 8492 | #75 |
| 2904 | #75 |
| 1334 | #75 |
| incidence bleeding events | #75 |
| retrospective follow | #75 |
| oral combined contraceptives | #76 |
| duration thromboprophylaxis | #76 |
| risk thrombosis | #76 |
| early time | #76 |
| angiography ctpa | #76 |
| extended anticoagulation | #76 |
| tests primary | #76 |
| factor xii deficiency | #76 |
| combined contraceptives | #76 |
| individual patient | #77 |
| boehringer | #77 |
| thrombosis pregnancy | #77 |
| p023 | #77 |
| patients secondary | #77 |
| social aspects | #77 |
| elevated dimer | #78 |
| women thrombophilia | #78 |
| 20 daily | #78 |
| arterial wall thickness | #78 |
| arterial thromboembolism | #78 |
| unprovoked | #78 |
| ipg | #78 |
| female fibrinolysis | #78 |
| efficacy agents | #79 |
| humans pulmonary | #79 |
| factor adult | #79 |
| time therapeutic | #79 |
| suspected acute | #79 |
| vkas | #79 |
| topic heparin | #79 |
| vte fvl | #79 |
| limulus test | #79 |
| 2486 | #79 |
| daily bid | #80 |
| patient data | #80 |
| sspe patients | #80 |
| suspected cancer | #80 |
| validation models | #80 |
| 95 05 | #80 |
| thromboembolism incidence | #80 |
| heterozygous deficiency | #80 |
| alife | #80 |
| subhazard ratio | #80 |
| bleeding mortality | #80 |
| vte rate | #80 |
| outpatient basis | #81 |
| prothrombin complex concentrate | #81 |
| walking distance | #81 |
| systemic inflammatory | #81 |
| knee arthroplasty patients | #81 |
| test evaluation | #81 |
| weitz | #81 |
| lmwh vte | #81 |
| vascular events | #81 |
| topic risk | #81 |
| symptomatic carriers | #82 |
| thrombosis thrombophilia | #82 |
| 50 micrograms | #82 |
| prospective validation | #82 |
| placebo women | #82 |
| 3month followup | #82 |
| thrombosis incidence | #82 |
| heparin prevention | #82 |
| crnmb | #82 |
| mammography patients | #82 |
| thrombolytic drugs | #82 |
| posthoc analysis | #82 |
| timeperiods | #82 |
| clinical sign | #82 |
| common practice | #82 |
| dimer patients | #83 |
| inhibitor dabigatran | #83 |
| 2213 | #83 |
| elective coronary | #83 |
| 287 | #83 |
| patients thrombi | #83 |
| bleeding women | #83 |
| bistro | #83 |
| screening humans | #84 |
| prophylactic dose | #84 |
| inhibitor rivaroxaban | #84 |
| normotensive patients | #84 |
| inherited thrombophilia | #84 |
| heparin treatment | #84 |
| healthcare setting | #84 |
| diagnostic outcome | #84 |
| duration therapy | #84 |
| anticoagulants antiphospholipid | #85 |
| peripheral vascular diseases | #85 |
| endotoxins | #85 |
| antithrombin iii protein | #85 |
| asymptomatic dvt | #85 |
| venous thrombosis patients | #85 |
| thrombosis svt | #85 |
| normal levels | #85 |
| rhapc | #86 |
| dabigatran vka | #86 |
| 75 microg | #86 |
| 4576 | #86 |
| major bleeding warfarin | #86 |
| 10⁶ | #86 |
| elevated ddimer levels | #86 |
| venovenous hemofiltration | #86 |
| post‐hoc analysis | #87 |
| clinical impact | #87 |
| ≤50 | #87 |
| vidas | #87 |
| avws | #87 |
| patients 28 | #87 |
| 95 100 | #87 |
| obstetric patients | #87 |
| acute venous | #87 |
| contact activation | #87 |
| internist | #88 |
| washout period | #88 |
| 3319 | #88 |
| venographic | #88 |
| cdr | #88 |
| 4 points | #88 |
| lmwhs | #88 |
| treatment incidence | #88 |
| aged multicenter | #88 |
| treatment statins | #88 |
| activation factor | #88 |
| stroke bleeding | #89 |
| smoking incidence | #89 |
| anticoagulants dabigatran | #89 |
| rates major bleeding | #89 |
| severe hf | #89 |
| costs patient | #89 |
| ddimer | #89 |
| cytokine release | #89 |
| safety noacs | #89 |
| adequate treatment | #89 |
| tests test | #89 |
| vte venous thromboembolism | #89 |
| unexplained recurrent | #89 |
| matisse | #89 |
| beta blockers | #89 |
| ventilation lung | #89 |
| reversal strategies | #89 |
| pediatric venous | #90 |
| venous thrombosis risk | #90 |
| primary thromboprophylaxis | #90 |
| vka dabigatran | #90 |
| new patients | #90 |
| outweighs | #90 |
| fibrinolytic factors | #90 |
| 2293 | #90 |
| popliteal vein | #90 |
| thrombophilic risk factors | #90 |
| 20210 | #91 |
| anticoagulants doacs | #91 |
| inconvenience | #91 |
| cdrs | #91 |
| perfusion ratio | #91 |
| thromboembolism pregnancy | #91 |
| agents hemorrhage | #91 |
| 60 95 | #91 |
| thrombosis women | #91 |
| pyridines pyridones | #91 |
| single intravenous | #92 |
| prophylaxis incidence | #92 |
| combined clinical | #92 |
| thrombotic disease | #92 |
| direct thrombin inhibitors | #93 |
| 95 years | #93 |
| incidence knee | #93 |
| scenario analyses | #93 |
| compression patients | #93 |
| anticoagulation reversal | #93 |
| rivaroxaban edoxaban | #93 |
| 125 patients | #94 |
| vte surgery | #94 |
| 1027 | #94 |
| hf severity | #94 |
| atherogenic lipid | #94 |
| test result | #94 |
| patients symptomatic | #94 |
| heparins | #94 |
| children vte | #94 |
| european consensus statement | #95 |
| direct oral anticoagulant | #95 |
| viia rfviia | #95 |
| 2 levels | #95 |
| xii deficiency | #96 |
| efficacy rivaroxaban | #96 |
| fondaparinux treatment | #96 |
| randomised crossover study | #96 |
| ddimer level | #96 |
| risk symptomatic | #96 |
| symptomatic vte | #96 |
| 6 12 months | #96 |
| difference rates | #97 |
| fibrin generation | #97 |
| haemophilia patients | #97 |
| pyrazoles pyridones | #97 |
| tpa release | #97 |
| symptomatic pulmonary embolism | #97 |
| studies evaluated | #97 |
| doacs risk | #97 |
| abnormal perfusion | #97 |
| invasive testing | #97 |
| hypercoagulable | #98 |
| 16slice | #98 |
| supervised exercise therapy | #98 |
| activated protein apc | #98 |
| pregnancy postpartum period | #98 |
| simplify | #98 |
| major bleed | #98 |
| essential thrombocythaemia | #98 |
| 2875 | #98 |
| unselected | #99 |
| probast | #99 |
| risk arterial | #99 |
| perfusion scintigraphy | #99 |
| hirudin | #99 |
| acute dvt | #99 |
| lmwh warfarin | #99 |
| 2·0 | #99 |
| fatty foods | #100 |
| warfarin patients | #100 |
| patient groups | #100 |
| gbd 2010 | #100 |
| doubleblind trial | #100 |
| previews | #100 |
| prevention recurrent | #100 |
| 3 trials | #100 |
| 1116 | #100 |
| increasing levels | #100 |
| morpholines | #101 |
| factor viia | #101 |
| aptts | #101 |
| factor vii factor | #101 |
| venous thromboembolism women | #102 |
| pts patients | #102 |
| 265 patients | #102 |
| low pretest probability | #102 |
| alternative diagnosis | #102 |
| enoxaparin fondaparinux | #102 |
| 40 microg | #102 |
| adjudicated | #103 |
| arthroscopic anterior | #103 |
| endogenous thrombin | #103 |
| cteph patients | #103 |
| doppler method | #103 |
| therapeutic consequences | #103 |
| 338 | #103 |
| pregnancy puerperium | #103 |
| assay variation | #104 |
| term treatment | #104 |
| apparent increase | #104 |
| separate analyses | #104 |
| heparin pregnancy | #104 |
| diagnostic imaging humans | #104 |
| antithrombin iii | #104 |
| recurrence women | #104 |
| partial restoration | #104 |
| absolute increase | #104 |
| fibrin degradation products | #104 |
| oral factor | #104 |
| embryo loss | #105 |
| conventional therapy patients | #105 |
| 7 children | #105 |
| 1089 | #105 |
| chest ray | #106 |
| blind double | #106 |
| fibrinolytic systems | #106 |
| thromboprophylaxis patients | #106 |
| study total | #106 |
| thrombosis age | #106 |
| 2479 | #106 |
| 314 | #106 |
| hospitalized patients hf | #106 |
| essentials | #106 |
| thrombophilia | #106 |
| elevated levels | #106 |
| definition classification | #107 |
| vte risk | #107 |
| ddimer levels | #107 |
| topic recurrence | #107 |
| survival cancer patients | #107 |
| thromboembolic | #107 |
| simplified version | #107 |
| human volunteers | #108 |
| post thrombotic syndrome | #108 |
| specific subgroups | #108 |
| noncancer patients | #108 |
| grade 1c | #108 |
| cardiovascular death stroke | #108 |
| patients cancer | #108 |
| 500μg | #109 |
| anticoagulants cohort | #109 |
| 1235 | #109 |
| viia | #109 |
| routine coagulation | #109 |
| synthetic pentasaccharide | #109 |
| 039 | #109 |
| factor mutation | #109 |
| thrombin antithrombin | #109 |
| embolism treatment | #109 |
| evaluation studies | #109 |
| cancer activity | #110 |
| thrombosis treated | #110 |
| vka doac | #110 |
| inferiority trial | #110 |
| primary safety | #110 |
| antiplasmin | #110 |
| subsequent pregnancy | #110 |
| embolism quality | #110 |
| humans intermittent | #111 |
| negative predictive 100 | #111 |
| siset | #111 |
| anticoagulants biomarkers | #111 |
| treatment risk factors | #111 |
| comparison control | #111 |
| obstetric complications | #111 |
| predefined | #111 |
| thromboembolic diseases | #112 |
| efficacy prevention | #112 |
| emergency situations | #112 |
| patients 70 | #112 |
| risk rivaroxaban | #112 |
| recurrence treatment | #112 |
| chromogenic | #112 |
| topic guidelines | #112 |
| patients ventricular dysfunction | #112 |
| rivaroxaban enoxaparin | #112 |
| publication anticoagulants | #112 |
| epidemiology risk factors | #112 |
| metabolic response | #113 |
| inappropriate treatment | #113 |
| heterozygous carriers | #113 |
| lmwh risk | #113 |
| patients nephrotoxicity | #113 |
| nonionic contrast | #113 |
| total knee replacement | #114 |
| study centre | #114 |
| postphlebitic syndrome | #114 |
| dialysers | #114 |
| cancerassociated vte | #114 |
| 0·0 | #114 |
| patients intermediate | #114 |
| patients recurrent | #115 |
| positive predictive values | #115 |
| hyperhomocysteinaemia | #115 |
| fibrinogen vwf | #115 |
| global public | #115 |
| 393 | #115 |
| life treatment | #116 |
| anticoagulants arthroplasty | #116 |
| reference standard | #116 |
| topic dabigatran | #116 |
| effects tnf | #116 |
| women severe preeclampsia | #116 |
| vte data | #116 |
| agents heparin | #116 |
| heparin warfarin | #116 |
| major bleeding 95 | #116 |
| computed tomography patients | #116 |
| arthroscopies | #117 |
| 2460 | #117 |
| protein resistance | #117 |
| vte children | #117 |
| protein inhibitor pci | #117 |
| fibrinolytic parameters | #117 |
| vte complications | #117 |
| women caesarean | #117 |
| 2744 | #118 |
| autopsyconfirmed | #118 |
| patients extensive | #118 |
| 4118 | #118 |
| proximal dvt | #118 |
| arterial thrombosis patients | #118 |
| compression stockings | #119 |
| incidence pulmonary embolism | #119 |
| compared warfarin | #119 |
| humans leg | #119 |
| patients doac | #119 |
| previous vte | #120 |
| thrombosis study | #120 |
| acquired deficiency | #120 |
| lactoferrin leukocyte | #120 |
| months follow | #120 |
| healthy humans | #120 |
| dabigatran factor | #120 |
| risk thromboembolism | #120 |
| mortality diseases | #120 |
| rivaroxaban patients | #120 |
| thrombocytopenia thrombosis | #121 |
| patients prostatic cancer | #121 |
| fatal pulmonary embolism | #122 |
| studies venous | #122 |
| patients 6 | #122 |
| oral hormonal | #122 |
| anti factor | #122 |
| placebo standard | #123 |
| venous thromboembolism pregnancy | #123 |
| heparin hirudin | #123 |
| acute infection | #123 |
| minor bleeding | #123 |
| early dynamics | #123 |
| heparin | #123 |
| 100 patients | #123 |
| factor xia | #123 |
| thrombophilia pregnancy | #124 |
| statin risk | #124 |
| vte lmwh | #124 |
| treatment data | #124 |
| atherogenic lipid profile | #124 |
| ft4 levels | #124 |
| association level | #124 |
| peripheral arterial disease | #125 |
| intravenous heparin | #125 |
| skin perfusion | #125 |
| incidence thrombosis | #125 |
| thromboembolism recurrence | #125 |
| elevated liver enzymes | #125 |
| fibrinolysis inhibitor | #125 |
| treatment indication | #125 |
| puerperal disorders | #125 |
| nonsignificantly | #125 |
| bayer | #125 |
| diseases mortality | #125 |
| upper extremity | #126 |
| doacs treatment | #126 |
| distal dvt | #126 |
| patients permanent | #127 |
| thromboprophylaxis lmwh | #127 |
| occurrence vte | #127 |
| marder | #127 |
| unacceptably | #127 |
| patients ventilation | #127 |
| performance scores | #127 |
| development vte | #128 |
| venous thromboembolism risk | #128 |
| resistance apc | #128 |
| 50 age | #128 |
| patients conventional therapy | #128 |
| direct factor | #128 |
| treatment months | #128 |
| prevention | #128 |
| riete registry | #129 |
| elevated biomarkers | #129 |
| mortality cancer patients | #129 |
| 060 | #129 |
| 1041 | #129 |
| ctrough | #129 |
| patients episode | #130 |
| 220 | #130 |
| day 10 | #130 |
| plaster cast | #130 |
| hospital discharge records | #130 |
| 194 patients | #130 |
| internists | #130 |
| anticoagulants antithrombins | #130 |
| tests specificity | #131 |
| pooled incidence | #131 |
| long‐term clinical outcomes | #131 |
| obviating | #131 |
| 05 patients | #131 |
| linear interpolation | #131 |
| rivaroxaban versus | #132 |
| postpartum period women | #132 |
| hypocoagulability | #132 |
| hoc analysis | #132 |
| cha2ds2vasc | #133 |
| started | #133 |
| 80 anticoagulants | #133 |
| fxa inhibitors | #133 |
| avidin | #133 |
| direct inhibitors | #133 |
| enoxaparin treatment | #133 |
| rco vwf | #134 |
| instituted | #134 |
| risk pad | #134 |
| embolism acute | #134 |
| pulmonary angiography patients | #134 |
| selectin levels | #134 |
| prevalence dvt | #135 |
| bnp concentration | #135 |
| activator plasminogen | #135 |
| anticoagulant prophylaxis | #135 |
| 0056 | #136 |
| east asian patients | #136 |
| thrombotic syndrome | #136 |
| months anticoagulation | #136 |
| clinical prediction | #136 |
| apixaban edoxaban | #136 |
| severe pph | #136 |
| followup patients | #136 |
| point‐of‐care | #137 |
| 2283 | #137 |
| factor prothrombin | #137 |
| phase 3 trials | #137 |
| sequential application | #137 |
| acquired thrombophilia | #137 |
| diagnostic work | #137 |
| 99 patients | #137 |
| intravascular coagulation dic | #138 |
| antidote | #138 |
| bleeding warfarin | #138 |
| studies mortality | #138 |
| complete inhibition | #138 |
| enhanced factor | #138 |
| national guidelines | #138 |
| oral anticoagulant treatment | #139 |
| factor viii factor | #139 |
| 2465 | #139 |
| 95 major bleeding | #139 |
| 3 weeks | #139 |
| reproducibility risk | #139 |
| patients comparison | #139 |
| direct inhibitor | #139 |
| risk fatal | #139 |
| vwf rco | #140 |
| distal deep | #140 |
| 12 95 | #140 |
| dvt incidence | #140 |
| 20 iu | #140 |
| 80 cohort | #140 |
| 0114 | #140 |
| ottawa | #140 |
| human activated | #140 |
| thromboembolic disorders | #141 |
| antidotes | #141 |
| pharmacy records | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| escherichia humans | #143 |
| jugular veins | #143 |
| geneva | #143 |
| warfarin administration | #143 |
| ischaemic events | #143 |
| treatment pulmonary | #143 |
| active malignancy | #143 |
| points 95 | #143 |
| management vte | #144 |
| fatal pulmonary | #144 |
| doac treatment | #144 |
| pregnancy female humans | #144 |
| postoperative venous | #144 |
| topic practice patterns | #144 |
| compared treatment | #144 |
| dose rivaroxaban | #145 |
| referred patients | #145 |
| thrombosis model | #145 |
| filters venous | #145 |
| hyperthyroxinemia | #145 |
| patient populations | #145 |
| serial testing | #145 |
| protein factor | #146 |
| death cancer patients | #146 |
| months treatment | #146 |
| derived microvesicles | #146 |
| tissue factor pathway | #147 |
| personal fees | #147 |
| 10 years patients | #148 |
| embolism diagnosis | #148 |
| partial thromboplastin | #148 |
| 2076 | #148 |
| acute medical illness | #148 |
| rebuttal | #148 |
| antithrombotic drugs | #148 |
| long‐acting | #148 |
| intention treat | #148 |
| individual patient data | #149 |
| 0·45 | #149 |
| thrombocyte | #149 |
| vte hospitalization | #149 |
| procoagulant | #149 |
| relevant publications | #149 |
| risk subgroups | #149 |
| diagnostic score | #149 |
| dimer level | #150 |
| additional imaging | #151 |
| coagulation dic | #151 |
| enoxaparin unfractionated heparin | #151 |
| humans injections | #151 |
| continuous venovenous | #152 |
| longterm treatment | #152 |
| patient eligibility | #152 |
| bleeding patients | #152 |
| patients primary outcome | #152 |
| thrombosis prevention | #153 |
| cardiopulmonary bypass surgery | #153 |
| extracorporeal circuit | #153 |
| hypercoagulable state | #153 |
| point systems | #153 |
| dimer levels | #154 |
| active cancer | #154 |
| angioplasty patients | #154 |
| thrombosis factor | #154 |
| bleeding scores | #154 |
| activity mortality | #154 |
| direct thrombin | #154 |
| states venous | #155 |
| thromboembolic event | #155 |
| tomography patients | #155 |
| warfarin apixaban | #155 |
| drug factor | #155 |
| fiia | #155 |
| curve sensitivity | #155 |
| vte treatment | #156 |
| recurrent symptoms | #156 |
| 09 | #156 |
| enoxaparin dose | #156 |
| fvl | #156 |
| daily oral | #156 |
| coagulant activity | #156 |
| patients gastrointestinal | #156 |
| stockings | #156 |
| hemodynamically | #157 |
| prophylaxis patients | #157 |
| cross‐sectional survey | #157 |
| increased thrombin | #157 |
| 2126 | #158 |
| dfl | #158 |
| 97 | #158 |
| duration anticoagulation | #158 |
| underlying malignancy | #158 |
| months chemotherapy | #158 |
| adjusted relative risk | #159 |
| increased risk thrombosis | #159 |
| guidelines prevention | #160 |
| antithrombotic efficacy | #160 |
| 145 patients | #160 |
| children fh | #160 |
| 120 minutes | #160 |
| thrombotic disorders | #160 |
| plasma dimer | #160 |
| schering | #160 |
| pvo | #161 |
| antagonists patients | #161 |
| prophylactics | #161 |
| women time | #162 |
| 2206 | #162 |
| lysine analogues | #162 |
| patients imaging | #162 |
| incidence vte | #162 |
| factors bleeding | #163 |
| strain gauge | #163 |
| coagulation blood | #163 |
| rates vte | #163 |
| venous thrombus | #163 |
| lmwh therapy | #163 |
| imaging test | #163 |
| increased plasma levels | #163 |
| 198 patients | #163 |
| 028 | #164 |
| age comorbidity | #164 |
| inborn humans | #164 |
| observer variability | #164 |
| justified | #164 |
| subhazard | #165 |
| relatives patients | #165 |
| patients enoxaparin | #165 |
| mutation factor | #165 |
| strategies patients | #166 |
| management venous thromboembolism | #166 |
| viii factor | #166 |
| phlebography | #166 |
| pravastatin therapy | #166 |
| microvascular thrombosis | #166 |
| stockings compression | #166 |
| 3658 | #167 |
| thrombin venous | #167 |
| recurrent thrombosis | #167 |
| ankle brachial abi | #167 |
| current clinical practice | #168 |
| cvcs | #168 |
| treatment 3 months | #168 |
| double heterozygosity | #168 |
| cstatistics | #168 |
| syndrome pts | #168 |
| recurrent acute | #168 |
| warfarin | #168 |
| preexistent | #169 |
| patients infections | #169 |
| therapeutic range | #169 |
| 3 12 | #169 |
| postthrombotic syndrome pts | #169 |
| risk profile | #169 |
| fold increased | #169 |
| postoperative blood loss | #170 |
| heavy menstrual bleeding | #170 |
| thrombosis cancer | #170 |
| interobserver agreement | #170 |
| cart patients | #170 |
| aged algorithms | #171 |
| 57 years | #171 |
| recombinant factor | #171 |
| venous thrombotic events | #171 |
| adamts‐13 | #171 |
| vaginal bleeding | #172 |
| patients blood transfusion | #172 |
| clinical trials patients | #172 |
| lmw heparin | #172 |
| risk factors patients | #172 |
| pulmonology | #172 |
| antifibrinolytic | #172 |
| pulmonary | #173 |
| hospitalized medical patients | #173 |
| bleeds | #173 |
| inr | #173 |
| clinically bleeding | #174 |
| laboratory monitoring | #174 |
| bleeding tendency | #174 |
| patients initial | #174 |
| arterial occlusions | #174 |
| reocclusion | #175 |
| arterial venous | #175 |
| data control | #175 |
| vte common | #175 |
| fragment 1 | #175 |
| prothrombin | #177 |
| picotamide | #177 |
| mitsubishi | #177 |
| hyperthyroidism hypothyroidism | #178 |
| 122 | #178 |
| short‐ | #178 |
| aspirin ticlopidine | #178 |
| intention analysis | #178 |
| noninferior | #179 |
| baseline day | #179 |
| vte event | #179 |
| concomitance | #179 |
| oral female humans | #179 |
| ventilation perfusion | #180 |
| isth | #180 |
| additional risk factors | #180 |
| referral bias | #180 |
| patients deficiency | #180 |
| thromboplastin time | #180 |
| aged partial | #181 |
| painkillers | #182 |
| acute episode | #182 |
| antithrombin | #182 |
| testing patients | #182 |
| hyperhomocysteinemic | #183 |
| patients major | #183 |
| 2–4 | #183 |
| biological variation | #183 |
| risk bleeding | #184 |
| 4150 | #184 |
| thromboinflammation | #184 |
| n110 | #184 |
| treat analysis | #184 |
| pregnancy vte | #184 |
| coagulation factors | #184 |
| incidental | #184 |
| subsequent diagnosis | #184 |
| prognosis pulmonary | #184 |
| antithrombin iii atiii | #184 |
| vte age | #185 |
| deficient patients | #185 |
| anticoagulated | #186 |
| hemostatic effects | #186 |
| live birth rate | #186 |
| studies heparin | #186 |
| patients intensive units | #186 |
| symptomatic | #186 |
| brain natriuretic | #186 |
| patients thromboprophylaxis | #186 |
| risk composite | #187 |
| cutoff level | #187 |
| safety apixaban | #187 |
| antifibrinolytic agents | #187 |
| patients haemophilia | #187 |
| doacs vkas | #188 |
| absolute rate | #188 |
| 926 | #188 |
| humans international | #188 |
| ratio inr | #188 |
| spontaneous rupture | #188 |
| prevalence cancer | #188 |
| willebrand factor antigen | #189 |
| viia female | #189 |
| fibrinolysis | #189 |
| 64slice | #189 |
| heparin administration | #189 |
| blood loss patients | #189 |
| riete | #189 |
| patients netherlands | #189 |
| clinical validity | #189 |
| thrombosis patients | #190 |
| ccus | #190 |
| ischemic event | #190 |
| current views | #190 |
| anticoagulant drugs | #190 |
| score patients | #191 |
| attending physicians | #191 |
| venous outflow | #191 |
| acute thrombosis | #191 |
| gogh | #191 |
| 07 | #191 |
| stroke systemic | #192 |
| 1495 | #192 |
| 058 | #192 |
| coagulation assays | #193 |
| endothelial cell activation | #193 |
| heparin patients | #194 |
| prothrombin activation | #194 |
| 070 | #194 |
| blood coagulation | #194 |
| anticoagulation | #194 |
| recurrent ischemic events | #195 |
| antixa levels | #195 |
| 65 months | #195 |
| risk major | #195 |
| target range | #195 |
| antagonist treatment | #195 |
| 29 95 | #196 |
| complications cardiovascular | #196 |
| coagulation status | #196 |
| abnormal test | #196 |
| ate | #198 |
| sew2871 | #198 |
| difference treatment | #198 |
| vwf adamts13 | #198 |
| treatment groups patients | #198 |
| vii rfviia | #198 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| patient diagnosis | #199 |
| obese controls | #200 |
| incidence cardiovascular events | #200 |
| patients 12 months | #200 |
| screening patients | #200 |
| patients abnormal | #201 |
| thrombin factor | #201 |
| validation sets | #201 |
| thromboembolic disease | #201 |
| vte incidence | #201 |
| johnson | #202 |
| 17 95 | #202 |
| arterial thrombosis | #202 |
| peritoneovenous | #202 |
| worldwide survey | #203 |
| symptomatic pad | #203 |
| induced activation | #203 |
| heparin dose | #203 |
| invitees | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| low incidence | #205 |
| period time | #205 |
| 0 95 | #205 |
| thrombophilia risk | #205 |
| extended thromboprophylaxis | #205 |
| stroke systemic embolism | #205 |
| venous ultrasonography | #206 |
| fgt | #206 |
| varese | #206 |
| data synthesis | #206 |
| patients anticoagulant therapy | #206 |
| algorithms anticoagulants | #207 |
| methods consecutive | #207 |
| fviii | #207 |
| systematic review studies | #207 |
| death female humans | #207 |
| platelet activation patients | #207 |
| desogestrel | #207 |
| 06 | #207 |
| objectively | #207 |
| imt patients | #207 |
| cardiologist | #207 |
| bleeding compared | #208 |
| thrombocythaemia | #208 |
| patients hypothyroidism | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| women frequency | #210 |
| tgt | #210 |
| antixa activity | #210 |
| hirudins | #210 |
| ioxaglate | #211 |
| toxaemia | #211 |
| systemic embolism patients | #211 |
| stocking | #211 |
| atrial fibrillation study | #212 |
| anticoagulation management | #212 |
| heparitin sulfate | #213 |
| plasminogen activator activity | #213 |
| dabigatran dose | #214 |
| topic practice | #214 |
| correct interpretation | #214 |
| studies rivaroxaban | #215 |
| thrombin inhibition | #215 |
| current developments | #215 |
| factors vte | #215 |
| standard duration | #215 |
| duplex venous | #216 |
| deamino | #216 |
| warfarin stroke | #216 |
| betatg | #216 |
| community hospital | #216 |
| obviates | #217 |
| undergoing total | #217 |
| diagnostic algorithm | #217 |
| mildest | #217 |
| studies difference | #217 |
| conclusive evidence | #218 |
| plasminogen activator inhibitor | #218 |
| cstatistic | #218 |
| npv 100 | #218 |
| g20210a | #218 |
| cancer | #219 |
| deamino arginine | #219 |
| patients cart | #219 |
| 077 95 | #219 |
| techniques female | #220 |
| vii factor | #220 |
| hip replacement surgery | #220 |
| data extraction | #220 |
| viii female | #220 |
| hmvec | #221 |
| preventive measures | #221 |
| heparin humans | #221 |
| healthy human subjects | #221 |
| postoperative vte | #221 |
| proximally | #222 |
| apc resistance | #222 |
| vte events | #222 |
| 1 january | #223 |
| engl | #223 |
| substantial proportion | #223 |
| pulmonologists | #223 |
| 1541 | #223 |
| thromboendarterectomy | #224 |
| protein pathway | #224 |
| topic factor | #224 |
| subsequent cancer | #224 |
| neoplasms prospective | #225 |
| thrombosis warfarin | #225 |
| org | #225 |
| kruskalwallis | #225 |
| balloon coronary anticoagulants | #225 |
| 0·67 | #226 |
| vascular events patients | #226 |
| inr monitoring | #226 |
| extremity amputation | #226 |
| 16 95 | #226 |
| acute medical | #227 |
| 35 ± | #227 |
| haemostasis | #227 |
| tests diagnosis | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| dalteparin | #229 |
| scant | #229 |
| residual thrombus | #229 |
| cgp | #229 |
| 037 | #230 |
| advocated | #230 |
| patients discontinuation | #231 |
| resource utilisation | #231 |
| habitual abortion | #231 |
| thiazoles | #231 |
| equinox | #231 |
| severe preeclampsia | #231 |
| 6 studies | #231 |
| major orthopaedic surgery | #231 |
| ft4 | #231 |
| urosepsis | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| cancer prevalence | #233 |
| recurrence risk factors | #233 |
| surgical embolectomy | #233 |
| anticoagulant effects | #233 |
| humans netherlands | #233 |
| endogenous thrombin potential | #233 |
| dimer | #233 |
| effective alternative | #234 |
| doac | #235 |
| prothrombotic state | #235 |
| graduated compression | #235 |
| humans meta | #236 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| oral anticoagulants | #237 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| 6500 | #238 |
| 009 | #238 |
| predictive tests | #238 |
| patients vkas | #238 |
| anticoagulants aspirin | #239 |
| factor tnf | #239 |
| crossover study | #239 |
| factor viii fviii | #239 |
| rational approach | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| hip knee arthroplasty | #241 |
| 045 | #241 |
| aspirin heparin | #241 |
| bleeding incidence | #242 |
| time therapeutic range | #242 |
| prothrombin fragment | #243 |
| patients intermittent claudication | #243 |
| pivotal trials | #243 |
| iohexol | #244 |
| vte risk factors | #245 |
| n89 | #245 |
| casecontrol | #246 |
| vte cases | #246 |
| children neonates | #246 |
| thrombogenesis | #246 |
| 23 95 | #247 |
| antithrombotic | #247 |
| lipoproteina levels | #247 |
| warfarin aged | #247 |
| committees | #248 |
| patients solid tumours | #248 |
| coronary anticoagulants | #248 |
| treatment compared | #248 |
| anti activity | #248 |
| diagnostic models | #249 |
| score risk | #249 |
| multiple comorbidities | #249 |
| bleeding rates | #249 |
| ioxaglic | #250 |
| fv leiden | #250 |
| ischemic strokes | #250 |
| protein risk | #250 |
| finalized | #251 |
| 8595 | #251 |
| patients contraindications | #251 |
| microthrombosis | #251 |
| simplification | #252 |
| somit | #252 |
| vkas doacs | #252 |
| incidence | #253 |
| thrombin thrombosis | #253 |
| treatment duration | #254 |
| agents anticoagulants | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| medea | #256 |
| haul | #256 |
| activation humans | #256 |
| activity assay | #257 |
| cost‐effectiveness | #257 |
| q24h | #257 |
| bleeding risk | #257 |
| continuous intravenous | #257 |
| clinical utility | #257 |
| fibrin degradation | #258 |
| patient subgroups | #258 |
| ctpa | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| dvt risk | #260 |
| sspe | #260 |
| thrombus size | #261 |
| heparin dosing | #261 |
| noncarriers | #261 |
| toxicosis | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| einstein | #267 |
| pbac | #267 |
| statins risk | #268 |
| endotoxaemia | #268 |
| lysis time | #269 |
| versus aspirin | #269 |
| propeptide | #269 |
| malignancy patients | #269 |
| randomised cross | #269 |
| relation time | #269 |
| single test | #270 |
| discontinuing | #270 |
| exclusion | #270 |
| protein patients | #270 |
| thrombosis inflammation | #271 |
| platelet serotonin | #271 |
| orthopaedic patients | #271 |
| hormonal replacement therapy | #271 |
| protein apc | #271 |
| 3·0 | #271 |
| bleeding patient | #272 |
| groups levels | #272 |
| patients combination | #272 |
| clopidogrel ticlopidine | #272 |
| vte recurrence | #272 |
| ankle brachial | #273 |
| efficacy analysis | #273 |
| months 12 | #274 |
| cleavage sites | #274 |
| risk levels | #274 |
| prevalence pad | #274 |
| international normalized | #275 |
| parenteral nutrition patients | #275 |
| performance score | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| imaging sensitivity | #278 |
| dose reduction | #278 |
| normalized ratio | #278 |
| blood test | #279 |
| aptt | #279 |
| rco | #279 |
| intracranial hemorrhage patients | #280 |
| propositi | #280 |
| exclusion criteria | #280 |
| obviate | #280 |
| partial thromboplastin time | #280 |
| hospitalized medical | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| thyroid diseases | #283 |
| puerperal | #283 |
| presentation patients | #283 |
| diagnostic sensitivity | #283 |
| neutrophil degranulation | #283 |
| test characteristics | #284 |
| favor | #284 |
| animals anticoagulants | #284 |
| noninferiority margin | #284 |
| departments | #284 |
| outpatient treatment | #284 |
| major orthopaedic | #285 |
| patients apixaban | #286 |
| 2630 | #286 |
| gentamicin treatment | #286 |
| plasma bnp | #286 |
| levels measured | #287 |
| patients pancreatic cancer | #287 |
| disseminated intravascular | #287 |
| clinically | #287 |
| subdistribution | #287 |
| 227 | #288 |
| oral combined | #288 |
| premature atherosclerosis | #288 |
| md patients | #288 |
| substantiation | #289 |
| vte rates | #289 |
| cvt patients | #289 |
| clot lysis | #289 |
| vte women | #289 |
| n59 | #290 |
| 0·50 | #290 |
| thrombin time | #290 |
| extracted data | #291 |
| current clinical | #291 |
| carriers mutation | #291 |
| oral contraceptives | #291 |
| 016 | #291 |
| willebrand disease vwd | #292 |
| 2 studies | #292 |
| 1603 | #292 |
| activator inhibitor | #292 |
| 1000 personyears | #293 |
| patients dabigatran | #293 |
| plasmin activity | #293 |
| adverse outcome patients | #293 |
| pentasaccharide | #293 |
| cardiac troponin ctnt | #294 |
| lower extremities | #294 |
| patients rivaroxaban | #294 |
| tissuetype plasminogen activator | #294 |
| extremity dvt | #295 |
| 1025 | #295 |
| scenario analysis | #295 |
| classified | #296 |
| peripheral vascular | #296 |
| coagulation factor viii | #296 |
| observer agreement | #297 |
| routine monitoring | #297 |
| episode patients | #298 |
| recurrent miscarriage | #298 |
| thrombocytes | #298 |
| specificity npv | #298 |
| patients inr | #299 |
| inferiority | #300 |
| 041 | #301 |
| heparitin | #301 |
| toxemia | #302 |
| aged neoplasms | #302 |
| thromboglobulin | #302 |
| 155 patients | #302 |
| subclinical thyroid dysfunction | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| medline embase | #306 |
| prophylactic administration | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| vte pregnancy | #310 |
| thrombotic | #310 |
| hematologic pregnancy | #310 |
| surgery day | #310 |
| patients 100 | #311 |
| percentage points | #311 |
| clinical presentation | #311 |
| 105 patients | #311 |
| antithrombins blood | #311 |
| 598 | #312 |
| leg male | #312 |
| negative reactions | #313 |
| hereditary thrombophilia | #313 |
| vte 95 | #313 |
| obesity risk factor | #313 |
| diagnosis | #314 |
| funding | #315 |
| heparin aspirin | #315 |
| puerperium | #315 |
| cardiologists | #315 |
| postpartum haemorrhage | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| 0·92 | #318 |
| deciding | #318 |
| safety outcomes | #319 |
| decision model | #319 |
| failure rates | #319 |
| influenza infections | #320 |
| catheter thrombosis | #320 |
| bnp levels | #320 |
| patients pregnancy | #320 |
| 1731 | #320 |
| combined administration | #320 |
| ventricular dysfunction patients | #321 |
| intermediate phenotype | #322 |
| patients noacs | #322 |
| additional data | #322 |
| difference risk | #322 |
| glaxosmithkline | #324 |
| inrs | #324 |
| peripheral arterial | #324 |
| mortality odds ratio | #325 |
| convincing evidence | #325 |
| blood coagulation factor | #326 |
| pulmonary embolus | #326 |
| 122 patients | #326 |
| mechanical heart valves | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| thrombotic event | #331 |
| incidence bleeding | #331 |
| pregnancy outcome women | #331 |
| vitamin administration | #331 |
| new oral | #332 |
| 95 percent | #333 |
| embase databases | #333 |
| analysis trials | #333 |
| n69 | #333 |
| incidences | #334 |
| complicate | #334 |
| minor effects | #334 |
| 95 confidence limits | #334 |
| rationale design | #335 |
| fibrillation benzimidazoles | #335 |
| patients healthy volunteers | #335 |
| central venous catheter | #336 |
| septicaemia | #336 |
| pulmonary perfusion | #336 |
| 2 points | #337 |
| plethysmographic | #337 |
| total hip replacement | #337 |
| recurrent | #337 |
| 035 | #337 |
| 065 | #337 |
| coagulation abnormalities | #338 |
| outpatient management | #338 |
| aged netherlands | #338 |
| fatal bleeding | #338 |
| placebo trials | #339 |
| prospective clinical study | #339 |
| noacs warfarin | #339 |
| 024 | #340 |
| patients 12 | #340 |
| antithrombotic effects | #340 |
| 217 | #341 |
| coagulation markers | #341 |
| activatable | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| vte prevention | #345 |
| rfviia | #345 |
| antithrombotic strategies | #345 |
| splanchnic vein thrombosis | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| activated protein resistance | #347 |
| patients thrombosis | #347 |
| 073 | #347 |
| 044 | #348 |
| cochrane central | #348 |
| bsf | #349 |
| 2575 | #349 |
| chads2 | #349 |
| brain predictive | #350 |
| trousseau | #350 |
| randomized studies | #350 |
| tafia | #350 |
| factor viii | #351 |
| versus warfarin | #351 |
| 013 | #351 |
| anticoagulants noacs | #352 |
| selection bias | #352 |
| factor activation | #352 |
| dermatan sulphate | #352 |
| vein | #353 |
| 5075 | #353 |
| 1590 | #353 |
| oral anticoagulant therapy | #353 |
| relative efficacy | #353 |
| aged pulmonary | #354 |
| international normalized ratio | #354 |
| patients gp | #355 |
| studies diagnostic accuracy | #355 |
| protein deficiency | #356 |
| categorised | #357 |
| intestinal microbiome | #357 |
| tests prospective studies | #357 |
| post hoc | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| treatment risk | #362 |
| consensus agreement | #362 |
| anticoagulation patients | #364 |
| humans risk | #365 |
| conventional therapy | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| time recurrence | #368 |
| patients 3 | #368 |
| infrainguinal | #368 |
| thrombin inhibitor | #369 |
| patients acl reconstruction | #370 |
| 6week | #370 |
| influenza infection | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 055 | #372 |
| 803 | #372 |
| recombinant activated | #373 |
| clinical suspicion | #373 |
| patients svt | #373 |
| knee surgery | #373 |
| aprotinin blood | #373 |
| human cytomegalovirus infection | #374 |
| helical computed tomography | #374 |
| patients scores | #374 |
| subcutaneous | #375 |
| hmb | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| stroke venous | #380 |
| contraceptives oral | #380 |
| tafi | #381 |
| ethinyloestradiol | #381 |
| antitnf | #382 |
| prefilter | #383 |
| multivariate regression analysis | #384 |
| thromboembolic complications | #384 |
| 0·8 | #384 |
| reassessed | #384 |
| standardized questionnaire | #384 |
| systemic activation | #385 |
| alpha2m | #385 |
| bleeding events | #386 |
| surrogate outcome | #386 |
| conference proceedings | #386 |
| antithrombins | #387 |
| sensitivity npv | #387 |
| cumulative incidences | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| 880 | #389 |
| safety rivaroxaban | #389 |
| referred | #389 |
| systemic embolism | #389 |
| tinzaparin | #390 |
| apixaban warfarin | #390 |
| vitt | #390 |
| comparison patients | #391 |
| drug prescription | #391 |
| biosis | #391 |
| increased bleeding | #391 |
| abi | #391 |
| postop | #391 |
| time presentation | #392 |
| patients chest | #392 |
| topic female humans | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| background patients | #394 |
| pulmonary emboli | #394 |
| clinical score | #394 |
| injections intravenous | #394 |
| 007 | #395 |
| 95 12 | #396 |
| bleeding event | #396 |
| popliteal | #396 |
| 665 | #397 |
| factors factor | #397 |
| embolic events | #397 |
| replacement surgery | #397 |
| hirudins humans | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| patients risk | #400 |
| echography | #400 |
| risk factors asthma | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| increased risk vte | #403 |
| controversy | #403 |
| dabigatran | #403 |
| massive pulmonary embolism | #405 |
| 2215 | #406 |
| 075 | #406 |
| treatment patient | #406 |
| thrombolytic agents | #406 |
| oral anticoagulant | #408 |
| factor levels | #408 |
| biologic effects | #410 |
| patients assigned | #411 |
| fviii levels | #411 |
| safety combination | #411 |
| noacs patients | #411 |
| 20 microg | #412 |
| transfusion patients | #412 |
| major risk factor | #412 |
| coagulation patients | #414 |
| maastricht | #414 |
| euthyroidism | #414 |
| aged odds | #415 |
| hypocortisolism | #415 |
| xii | #415 |
| intravascular coagulation | #416 |
| pai1 levels | #416 |
| dose heparin | #416 |
| deserve | #416 |
| comparable | #417 |
| 95 10 | #417 |
| data risk | #417 |
| 95 | #418 |
| pretest probability | #418 |
| carotid femoral | #418 |
| risk factors thrombosis | #419 |
| 269 | #419 |
| dermatan | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| fibrillation clinical | #422 |
| 2850 | #422 |
| 1989 | #422 |
| tests radiography | #422 |
| fibrinolysin | #423 |
| subanalysis | #424 |
| fviia | #424 |
| prevalence patients | #425 |
| fii | #426 |
| adjunct | #426 |
| randomised double | #426 |
| cancer cohort | #426 |
| activated factor | #427 |
| consecutive | #427 |
| excessive bleeding | #428 |
| daily practice | #428 |
| conferences | #428 |
| plg | #428 |
| daily clinical practice | #429 |
| idiopathic myelofibrosis | #429 |
| undergoing elective | #429 |
| prolactin levels | #429 |
| patients testing | #429 |
| 1904 | #430 |
| rule | #431 |
| heparinoids | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| bolus injection | #437 |
| 059 | #437 |
| dose adjustment | #439 |
| composite point | #439 |
| women compared | #439 |
| proven | #439 |
| prostatic cancer | #439 |
| concomitant medications | #441 |
| highrisk populations | #441 |
| 074 | #442 |
| rate vte | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| hellp | #449 |
| 58 | #449 |
| patients parenteral nutrition | #449 |
| utrecht | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| aspirin risk | #453 |
| noninvasive tests | #453 |
| thrombin generation | #453 |
| fatal disease | #453 |
| placebo day | #454 |
| portal blood | #454 |
| 30 40 | #454 |
| factor xii | #454 |
| 12week | #455 |
| microthrombi | #455 |
| 026 | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| dicumarol | #457 |
| onwards | #457 |
| squibb | #457 |
| anti levels | #458 |
| iii complexes | #458 |
| hazard ratio 95 | #458 |
| recommend | #460 |
| svt | #460 |
| plasma lipoprotein | #460 |
| factor fxa | #461 |
| gastrointestinal cancer | #461 |
| curve biomarkers | #462 |
| hip arthroplasty replacement | #462 |
| expert consensus document | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| studies ultrasonography | #464 |
| patients values | #464 |
| gp iib | #464 |
| month follow | #465 |
| cancerassociated thrombosis | #466 |
| diabetes stroke | #466 |
| accuracy detection | #467 |
| thrombin formation | #467 |
| intimamedia thickness | #468 |
| prophylaxis | #468 |
| patients nsaids | #468 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| test probability | #470 |
| hemihepatectomy | #470 |
| 077 | #470 |
| inr patients | #470 |
| roc analysis | #470 |
| placebo recipients | #471 |
| prophylactic anticoagulation | #472 |
| hypercoagulability | #472 |
| case control study | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| 15 95 | #475 |
| plethysmograph | #475 |
| patients heparin | #475 |
| endotoxemia | #475 |
| heterozygote humans | #475 |
| intermittent pneumatic | #475 |
| atria | #477 |
| 08 | #479 |
| patients score | #479 |
| haemophiliacs | #479 |
| versus standard | #480 |
| acutely | #481 |
| thrombosis cvt | #481 |
| hit patients | #481 |
| transportability | #482 |
| advisory | #482 |
| 1162 | #482 |
| postoperative blood | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| secondary prophylaxis | #487 |
| composite scores | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| hemophilic | #493 |
| new therapy | #493 |
| treatment period | #493 |
| pan troglodytes | #493 |
| p00007 | #493 |
| residual risk | #493 |
| vcf | #494 |
| activated protein | #495 |
| heterozygote | #496 |
| replacement hip arthroplasty | #496 |
| dose oral | #496 |
| favour | #496 |
| 271 | #497 |
| topic risk factors | #497 |
| willebrand disease | #498 |
| blockages | #498 |
| discriminative ability | #498 |
| risk factors stroke | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| subcategories | #503 |
| deficiencies | #503 |
| ft4 tsh | #503 |
| rapid decrease | #504 |
| patients referred | #505 |
| complications pulmonary | #505 |
| 1107 | #505 |
| nondiagnostic | #505 |
| net clinical | #506 |
| 310 | #506 |
| day surgery | #507 |
| oftentimes | #507 |
| nonionic | #507 |
| inhibitors rivaroxaban | #508 |
| aminocaproates | #509 |
| 13 95 | #509 |
| guidelines diagnosis | #509 |
| contraceptives | #509 |
| coagulation tests | #509 |
| thrombosis animals | #510 |
| new oral anticoagulants | #510 |
| angiography patients | #510 |
| degradation products | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| highintensity | #514 |
| interim analysis | #514 |
| 056 | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| bleeding outcomes | #518 |
| sensitivity diagnosis | #518 |
| thrombophilia thrombosis | #518 |
| thrombotic diseases | #518 |
| protein antithrombin | #518 |
| groups treatment | #519 |
| treatment cancer patients | #519 |
| study sensitivity | #520 |
| 1599 | #521 |
| duration intensity | #521 |
| 8090 | #521 |
| warfarin therapy | #524 |
| general practitioner | #525 |
| fixed doses | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| 378 | #529 |
| convincing | #529 |
| 051 | #529 |
| 923 | #529 |
| fatal | #530 |
| health female | #530 |
| medically patients | #531 |
| thrombosis hemostasis | #531 |
| betaalanine | #531 |
| humans postoperative | #531 |
| intensive units icu | #532 |
| 068 | #532 |
| thrombosis risk | #532 |
| ≥50 years | #532 |
| factor thrombin | #534 |
| therapy cancer | #534 |
| 730 | #536 |
| factor pathway | #537 |
| 449 | #538 |
| patients idiopathic | #538 |
| humans neoplasms | #538 |
| concise | #539 |
| cbo | #539 |
| comprehensive search | #539 |
| ddavp | #539 |
| clinical review | #540 |
| diagnosis acute | #540 |
| diagnostic accuracy studies | #540 |
| thrombotic risk | #543 |
| patients eligible | #543 |
| bleeding episodes | #543 |
| conventional treatment | #543 |
| vascular obstruction | #543 |
| 234 | #543 |
| coagulative | #544 |
| 00 | #544 |
| jak2 mutation | #544 |
| pad abi | #544 |
| prospective cohort study | #545 |
| hellp syndrome | #545 |
| perc | #545 |
| v617f | #545 |
| screening strategies | #546 |
| association statin | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| 95 difference | #549 |
| overt | #549 |
| adequate | #549 |
| percent patients | #550 |
| 1103 | #550 |
| cancer type | #550 |
| reviewers | #550 |
| platelet inhibitors | #550 |
| conduction anesthesia | #550 |
| studies sensitivity | #552 |
| careful | #552 |
| day patients | #552 |
| 500 patients | #552 |
| management bleeding | #552 |
| amsterdam | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| 66 patients | #558 |
| vivo treatment | #558 |
| factor vii | #558 |
| bleeding time | #559 |
| orthopedic surgery | #559 |
| limulus | #561 |
| risk development | #563 |
| board directors | #563 |
| female humans tests | #563 |
| patients transfusion | #563 |
| hip replacement | #564 |
| anamnesis | #564 |
| appears | #564 |
| hyperfibrinolysis | #565 |
| increasing risk | #565 |
| cardiac troponins | #566 |
| withholding | #566 |
| solid tumours | #566 |
| patients 2 years | #568 |
| roc curves | #568 |
| n46 | #568 |
| alpha1antitrypsin | #571 |
| levothyroxine | #571 |
| aggravation | #572 |
| ctnt | #573 |
| cutoff point | #574 |
| menstrual bleeding | #574 |
| revascularization procedures | #574 |
| subcutaneously | #575 |
| major bleedings | #575 |
| women proportion | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| pharma | #579 |
| endotoxin | #579 |
| thiophenes | #579 |
| 99 | #580 |
| notice | #580 |
| diagnostic tools | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| dummy | #584 |
| unselected patients | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| major orthopedic surgery | #588 |
| feasibility safety | #588 |
| helminth proteins | #589 |
| beta alanine | #590 |
| malignancy | #590 |
| reversal agents | #590 |
| thrombophilias | #590 |
| healthy human | #590 |
| conventional management | #592 |
| massive pulmonary | #592 |
| doppler ultrasound | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| severe bleeding | #597 |
| replacement knee | #597 |
| patency rates | #597 |
| major hemorrhage | #597 |
| ldf | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| tests sensitivity | #600 |
| loss surgical | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| clinical characteristics patients | #604 |
| comorbid conditions | #604 |
| events occurred | #604 |
| diagnostic studies | #606 |
| activated coagulation | #607 |
| 0·3 | #607 |
| patients antibodies | #607 |
| initial increase | #607 |
| treatment acute | #608 |
| arbitrage | #609 |
| tissue factor | #609 |
| pfizer | #609 |
| 100 years | #610 |
| benefit risk | #610 |
| patients death | #610 |
| airline | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| leg | #615 |
| reluctant | #615 |
| patients bariatric surgery | #615 |
| complications risk | #616 |
| arterial disease | #617 |
| treatment rivaroxaban | #617 |
| 467 | #618 |
| occurred | #618 |
| stroke atrial fibrillation | #618 |
| compared placebo | #620 |
| fh patients | #620 |
| advisory committees | #621 |
| patients elevated | #621 |
| 1002 | #622 |
| thrombocytopenia hit | #623 |
| sgs | #623 |
| thyrotoxic | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| warfarin risk | #628 |
| 66 | #628 |
| women risk factors | #628 |
| 5000 | #628 |
| physical training | #629 |
| human subjects | #629 |
| diagnostic algorithms | #629 |
| referral patients | #629 |
| absolute | #630 |
| sanofi | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| proceedings | #641 |
| study quality | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| threatening bleeding | #643 |
| neutrophilia | #643 |
| primary outcome measure | #647 |
| association mortality | #647 |
| statin treatment | #648 |
| studies efficacy | #648 |
| necessitating | #648 |
| thrombolysis patients | #651 |
| 036 | #651 |
| fixed | #651 |
| organisations | #652 |
| troglodytes | #652 |
| hemorrhagic stroke | #653 |
| fxa | #653 |
| 127 | #655 |
| patients review | #657 |
| 69 | #659 |
| coronary stent implantation | #659 |
| bleeding death | #659 |
| haematoma | #660 |
| coagulation proteins | #661 |
| physical examination | #661 |
| tertiles | #661 |
| haemophilia | #662 |
| clinical presentations | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| guideline adherence | #667 |
| presence patients | #667 |
| patients completed | #667 |
| onethird | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| managing | #674 |
| hospitalization hf | #674 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| clotting factors | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| graduated | #693 |
| activator pa | #693 |
| myocardial infarctions | #693 |
| administer | #694 |
| intracranial bleeding | #694 |
| composite outcome | #694 |
| precise mechanisms | #694 |
| 1718 | #695 |
| moyamoya | #696 |
| stroke prevention patients | #696 |
| combined oral contraceptives | #696 |
| participant data | #698 |
| difference 95 | #698 |
| ratio male | #698 |
| episode | #700 |
| compression devices | #700 |
| prothrombin gene | #702 |
| therapeutic management | #702 |
| diagnostic errors | #702 |
| patients confirmed | #703 |
| veins venous | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| gastrointestinal bleeding | #712 |
| gynaecology | #712 |
| 048 | #712 |
| medical patients | #712 |
| radionuclide imaging | #713 |
| neurosurgical patients | #714 |
| rate death | #714 |
| 1098 | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| cancer groups | #717 |
| adequately | #717 |
| 10 30 | #718 |
| solid cancer | #718 |
| falsely | #718 |
| plasminogen | #719 |
| reagent kits | #719 |
| pulmonary medicine | #720 |
| accp | #721 |
| pyrazoles pyridines | #721 |
| clinical judgment | #721 |
| nordisk | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| follow period | #726 |
| abnormal | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| diagnostic therapeutic | #728 |
| orthopaedic surgery | #728 |
| diagnostic tests | #730 |
| leeches | #732 |
| gentamicin | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| patients levels | #735 |
| disease pad | #735 |
| hull | #735 |
| atrial fibrillation risk | #736 |
| tests retrospective studies | #736 |
| clinical prediction rule | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| early pregnancy loss | #742 |
| 040 | #742 |
| unclear | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| molecular weight | #744 |
| betathromboglobulin | #744 |
| 285 | #746 |
| patients 50 years | #746 |
| antithrombin activity | #746 |
| etp | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| 95 combination | #756 |
| answer | #756 |
| 95 risk factors | #756 |
| pneumatic compression | #756 |
| hf risk | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| 85 | #759 |
| loe | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| 435 | #763 |
| proportion women | #763 |
| cprs | #764 |
| start treatment | #764 |
| hip surgery | #765 |
| aspirin clopidogrel | #767 |
| 689 | #767 |
| risk pregnancy | #767 |
| 732 | #768 |
| method drug | #769 |
| groups patients | #770 |
| relevant | #770 |
| 566 | #770 |
| graft patency | #772 |
| baseline values | #772 |
| patients criteria | #773 |
| subcutaneous injections | #774 |
| bmi patients | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose intravenous | #778 |
| study groups | #778 |
| patients 65 years | #778 |
| dose warfarin | #778 |
| miscarriage | #779 |
| patients hyperthyroidism | #780 |
| plasmin generation | #780 |
| thromboembolism prophylaxis | #780 |
| 066 | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| topic disease models | #787 |
| 100 personyears | #787 |
| polypharmacy | #787 |
| general practitioners | #787 |
| cteph | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| mechanical heart | #793 |
| recombinant tissue | #793 |
| 047 | #795 |
| inactivators | #795 |
| risk factors risk | #795 |
| patency | #796 |
| patient years | #796 |
| eligible | #797 |
| netherlands | #797 |
| studies prevalence | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| theme | #799 |
| estrogen therapy | #799 |
| patients lower | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| adverse outcomes patients | #806 |
| fibrillation blood | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| hypertension cteph | #809 |
| efficacy patients | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| irrespective | #820 |
| vehicle control | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| reduction mortality | #823 |
| prevention patients | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| gp | #828 |
| cardioembolic stroke | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| 93 | #833 |
| antithrombotic treatment | #833 |
| myers | #833 |
| abortion habitual | #835 |
| oral adult | #836 |
| plough | #836 |
| versus placebo | #837 |
| noac | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| antithrombotic therapy | #846 |
| 49 | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| reference method | #853 |
| 30 patients | #853 |
| pre‐eclampsia | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| favoring | #873 |
| tasman | #873 |
| targeted inhibition | #874 |
| imaging reproducibility | #874 |
| thromboembolic pulmonary | #874 |
| plasminogen activation | #875 |
| titles | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| dabigatran rivaroxaban | #878 |
| risk thromboembolic | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| domiciliary | #894 |
| male mexico | #894 |
| p011 | #896 |
| loading dose | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| patients clinical trials | #911 |
| documented | #911 |
| initially | #912 |
| haemostatic | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| haemodialysis patients | #916 |
| combined approach | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| antagonist oral | #920 |
| randomeffects model | #920 |
| standard patients | #920 |
| loss patients | #921 |
| ultrasound examination | #921 |
| optimal dose | #921 |
| estimate male | #923 |
| practise | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| wording | #934 |
| treatment placebo | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| stroke atrial | #944 |
| women preeclampsia | #944 |
| echocardiographically | #944 |
| emboli | #945 |
| ssc | #946 |
| predictive values | #946 |
| anticoagulation treatment | #947 |
| extensive disease | #948 |
| knee replacement | #948 |
| diagnostic | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| network metaanalysis | #956 |
| registro | #956 |
| cancer humans | #956 |
| dic | #956 |
| reassuring | #957 |
| venous insufficiency | #957 |
| efficacy | #958 |
| day1 | #958 |
| combined oral | #961 |
| retropubic | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| inhibitor1 | #966 |
| reference lists | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| prevalence characteristics | #973 |
| hoc | #973 |
| risk allcause mortality | #973 |
| antiplatelet | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| 071 | #980 |
| onset aged aged | #980 |
| 50 100 | #980 |
| early gestation | #984 |
| 426 | #986 |
| randomised trials | #987 |
| prophylactic treatment | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| seminar | #992 |
| academic medical center | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| aged | #999 |
| 226 | #999 |
| lower extremity | #1000 |
| justification | #1000 |
| thromboembolic risk | #1000 |
| tissue type | #1001 |
| parenteral administration | #1002 |
| rivaroxaban apixaban | #1002 |
| eclamptic | #1003 |
| interleukin 6 | #1005 |
| hyperprolactinaemia | #1005 |
| extended | #1005 |
| pyridines | #1006 |
| easier | #1007 |
| 50 patients | #1007 |
| orthosis | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| pounds | #1018 |
| ticlopidine | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| cha2ds2 vasc | #1023 |
| years risk | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| decision analysis | #1030 |
| firstdegree relatives | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| relatives | #1033 |
| risk hemorrhage | #1033 |
| cardiovascular event | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| vwf levels | #1047 |
| patients severe asthma | #1047 |
| examiner | #1050 |
| patients massive | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| 221 | #1054 |
| mean±sd | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| birth rate | #1060 |
| coagulant | #1060 |
| 179 | #1060 |
| pad | #1061 |
| 610 | #1061 |
| primary data | #1062 |
| published literature | #1062 |
| false | #1064 |
| 150 | #1065 |
| prekallikrein | #1065 |
| live birth | #1066 |
| 00008 | #1066 |
| 101 | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| 95 increased risk | #1070 |
| register controlled | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| 063 | #1080 |
| advocate | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| clarifications | #1095 |
| stopping | #1095 |
| diagnostic utility | #1096 |
| idarucizumab | #1096 |
| mandated | #1096 |
| 1223 | #1099 |
| 083 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| clinical protocols | #1107 |
| peptide brain | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| bypass grafts | #1116 |
| haemodialysis | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| heparininduced thrombocytopenia | #1127 |
| cip | #1127 |
| patients pad | #1128 |
| judged | #1132 |
| discretion | #1132 |
| ≤10 | #1133 |
| statistic | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| superior efficacy | #1141 |
| 635 | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| anticoagulation therapy | #1156 |
| blood loss | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| intermittent | #1164 |
| safety concerns | #1164 |
| viii | #1164 |
| stable angina | #1164 |
| hyperhomocysteinemia | #1164 |
| age 65 years | #1165 |
| thromboembolism risk | #1165 |
| angiogram | #1167 |
| perioperative bleeding | #1172 |
| crossover design | #1172 |
| glucocorticoid treatment | #1172 |
| atherosclerotic disease | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| analysis studies | #1178 |
| findings patients | #1178 |
| 79 | #1179 |
| conceive | #1181 |
| concealed | #1181 |
| hospitalized patients | #1182 |
| unaware | #1182 |
| patients obesity | #1182 |
| conclusive | #1186 |
| combined therapy | #1186 |
| degree relatives | #1189 |
| occult | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| mandate | #1199 |
| international society | #1199 |
| cardiotonic agents | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| categorized | #1204 |
| quantitative trait locus | #1204 |
| 015 | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| pph | #1214 |
| multicenter randomized | #1214 |
| 103 | #1218 |
| scores patients | #1221 |
| patient treatment | #1221 |
| warranted | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| peak levels | #1224 |
| 64 patients | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| metabolic syndrome patients | #1228 |
| consensus guidelines | #1228 |
| peptide hydrolases | #1229 |
| trial background | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| milliliter | #1238 |
| postoperative hemorrhage | #1238 |
| coronary angiography patients | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| ml1 | #1252 |
| subgroups | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| oral vitamin | #1257 |
| search strategy | #1257 |
| extensive | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| visiting | #1266 |
| entity | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| intensive patients | #1274 |
| equally | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| statin users | #1281 |
| routine screening | #1281 |
| 75 years | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| perfusion defects | #1295 |
| scan | #1295 |
| janssen | #1295 |
| hemofiltration | #1297 |
| predictive | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| cyproterone | #1312 |
| apoa | #1312 |
| risk difference | #1312 |
| 1st | #1312 |
| adamts13 activity | #1313 |
| current strategies | #1314 |
| 0·7 | #1314 |
| tests severity | #1314 |
| atrial fibrillation | #1316 |
| claudication | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| glycoprotein gpiib | #1325 |
| lipoproteina | #1325 |
| patients coronavirus disease | #1326 |
| antibodies monoclonal antibodies | #1329 |
| vascular diseases | #1329 |
| beneficial | #1329 |
| plasminogen activators | #1330 |
| low moderate | #1330 |
| thyroid disorders | #1330 |
| coagulation cascade | #1331 |
| 6 months patients | #1331 |
| 77 | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| antitrypsin | #1347 |
| surgical trauma | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| experimental model | #1359 |
| allcause mortality 95 | #1359 |
| 15 patients | #1359 |
| vwf | #1363 |
| arsenal | #1363 |
| limb salvage | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| noninferiority | #1385 |
| 224 | #1385 |
| dl1 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| record linkage | #1400 |
| patients control subjects | #1400 |
| antisense oligonucleotide | #1402 |
| equipoise | #1402 |
| 82 | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| categories | #1408 |
| 515 | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 3 6 | #1419 |
| thrombotic complications | #1419 |
| 6 weeks | #1419 |
| 7 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| followup data | #1422 |
| university hospitals | #1422 |
| 061 | #1424 |
| ≥55 | #1424 |
| daily | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| casecontrol study | #1430 |
| rgs | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| drug levels | #1446 |
| weight bmi | #1446 |
| outcome studies | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| aged blood | #1455 |
| platelet factor | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| funded | #1466 |
| actual | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| 1215 | #1473 |
| prevalences | #1473 |
| centrally | #1474 |
| systemic infection | #1477 |
| probability | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| analysis randomized | #1485 |
| cushing syndrome | #1485 |
| phase iii trials | #1486 |
| methodologic | #1486 |
| general practice | #1491 |
| patients control | #1495 |
| procoagulant activity | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| adverse outcome | #1514 |
| growing body | #1514 |
| proximal | #1516 |
| pregnancy postpartum | #1520 |
| patients 10 | #1520 |
| ganz | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| live births | #1552 |
| patients severe sepsis | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| topic | #1566 |
| treatment prevention | #1566 |
| 95ci | #1568 |
| cushings syndrome | #1568 |
| hyperlipoproteinemia type | #1568 |
| deficient | #1568 |
| aged biomarkers | #1571 |
| plasminogen activator | #1575 |
| 36 | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| activation markers | #1586 |
| study entry | #1586 |
| cocs | #1586 |
| thyroid dysfunction | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| total mortality | #1594 |
| 1·1 | #1594 |
| translates | #1597 |
| placebo | #1598 |
| noncancer | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| tests reproducibility | #1616 |
| prospective cohort studies | #1616 |
| factors tomography | #1616 |
| positive effects | #1616 |
| postpartum period | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| imaging tomography | #1619 |
| female hemostasis | #1619 |
| cvd patients | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| pa patients | #1632 |
| incidentally | #1632 |
| venous disease | #1632 |
| fresh frozen plasma | #1633 |
| clinical patients | #1633 |
| study outcomes | #1639 |
| double | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| ctni | #1644 |
| stroke prevention | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| ≤4 | #1652 |
| 35 years | #1652 |
| thrombin activity | #1653 |
| studies data | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| disease adult | #1670 |
| homocysteine levels | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| deficiency | #1677 |
| plasma level | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| unreliable | #1686 |
| steroidal anti | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| 033 | #1712 |
| yielded | #1712 |
| intravenous | #1715 |
| hemorheology | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| female femoral | #1721 |
| diagnostic evaluation | #1721 |
| mb | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| 107 | #1726 |
| conference | #1726 |
| derived microparticles | #1729 |
| 021 | #1730 |
| volunteer | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| east asian | #1735 |
| clinical scores | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| table | #1745 |
| 691 | #1745 |
| patients ventricular | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| apc | #1749 |
| turp | #1749 |
| pselectin | #1750 |
| replacement | #1750 |
| homozygosity | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| assessor | #1760 |
| audiometry | #1760 |
| treatment recommendations | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| fx | #1764 |
| human insulin | #1764 |
| duplicate | #1769 |
| initial management | #1770 |
| hemorrhage | #1770 |
| arteriosclerosis | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| cardiac troponin | #1794 |
| vascular surgical | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| tumor necrosis | #1812 |
| 95 specificity | #1812 |
| slc6a4 | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| economic evaluation | #1819 |
| conjoint | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| cushing | #1838 |
| kaplanmeier estimate | #1838 |
| severe sepsis | #1839 |
| central venous | #1842 |
| 1 week | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| diagnostic testing | #1901 |
| extremity | #1901 |
| tnf | #1901 |
| clt | #1905 |
| plaster | #1906 |
| hazard ratio | #1906 |
| induced thrombocytopenia | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| referral | #1910 |
| efficacy treatment | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| 868 | #1923 |
| stroke 95 | #1923 |
| biotin | #1924 |
| 55 years | #1924 |
| trials patients | #1926 |
| venous pressure | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| 3months | #1935 |
| relative risks | #1935 |
| 17 | #1936 |
| acute | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| observer | #1962 |
| investigators | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| 48 hours | #1973 |
| fibrin clot | #1973 |
| surgical blood | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| 771 | #1981 |
| specificity ultrasonography | #1981 |
| hyperaldosteronism | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| treatment cancer | #1986 |
| 1·0 | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| cvt | #1995 |
| computerized | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| clinical severity | #2000 |
| transient increase | #2000 |
| 3 months patients | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| mongrel | #2017 |
| angina unstable | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| prediction rule | #2045 |
| thrice | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| superior vena cava | #2051 |
| quartiles | #2051 |
| inadequately | #2052 |
| 277 | #2053 |
| pregnancy trimester | #2053 |
| controversial | #2055 |
| adherence guidelines | #2056 |
| stent implantation | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| national institute | #2074 |
| 188 | #2074 |
| mcnemar | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| square distribution | #2092 |
| 114 | #2092 |
| tissue plasminogen | #2093 |
| reference range | #2099 |
| preformed | #2099 |
| 038 | #2100 |
| 59 | #2101 |
| desmopressin | #2101 |
| lifetime risk | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 1966 | #2109 |
| 031 | #2109 |
| substantial | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| independently | #2118 |
| unnecessary | #2118 |
| initial | #2119 |
| exists | #2119 |
| development validation | #2120 |
| coronary stent | #2122 |
| clinicaltrialsgov | #2122 |
| 11 | #2122 |
| acl reconstruction | #2125 |
| original | #2125 |
| topic surveys | #2127 |
| patients cardiovascular disease | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| protamines | #2134 |
| congress | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| clot | #2145 |
| live | #2145 |
| professionals | #2146 |
| bodyweight | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| giant cell arteritis | #2185 |
| 2 × | #2185 |
| fifty | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| pravastatin | #2205 |
| increased patients | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| 94 | #2225 |
| differential female | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| method female | #2324 |
| humans myocardial | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| lacked | #2344 |
| inhibitor | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| risk bias | #2375 |
| 099 | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| enrolling | #2379 |
| acute coronary syndromes | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| protein | #2413 |
| periodicals | #2413 |
| postinjection | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| sensitivity 100 | #2426 |
| guidelines | #2426 |
| legs | #2430 |
| 002 | #2430 |
| 0048 | #2430 |
| coagulants | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| turbidimetry | #2448 |
| 719 | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| therapy acute | #2468 |
| nephrotoxic | #2468 |
| comprised | #2469 |
| 477 | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| 648 | #2485 |
| pathway inhibitor | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| duration | #2493 |
| chest | #2493 |
| 25 | #2495 |
| illness tomography | #2503 |
| 616 | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| 463 | #2521 |
| neutrophil extracellular traps | #2521 |
| 152 | #2523 |
| accurate diagnosis | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 874 | #2537 |
| 164 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| haematology | #2560 |
| hours | #2560 |
| hydroxyethyl | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| kits | #2574 |
| humans logistic | #2574 |
| 73 | #2574 |
| pill | #2575 |
| prevalence | #2575 |
| patients total | #2577 |
| translate | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| burden disease | #2605 |
| manifest | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| patients 2 | #2608 |
| fatal outcome | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| cost analysis | #2620 |
| aviation | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| coincided | #2635 |
| chondroitin | #2635 |
| trials rcts | #2635 |
| 10 day | #2637 |
| attractive | #2641 |
| 345 | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| outcome ultrasonography | #2683 |
| 516 | #2683 |
| iii | #2685 |
| initial dose | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| dose low | #2732 |
| management strategies | #2732 |
| cart | #2736 |
| 595 | #2737 |
| 427 | #2739 |
| classifications | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| patients asthma | #2747 |
| baseline characteristics | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| alpha animals | #2772 |
| active control | #2775 |
| inpatient | #2776 |
| thrombomodulin | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| 402 | #2802 |
| consecutive series | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| 406 | #2813 |
| follow studies | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| antiplatelet drugs | #2826 |
| bid | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| kruskal | #2839 |
| crossover | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| trimester pregnancy | #2880 |
| excessive | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| 21 | #2897 |
| systematic review metaanalysis | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| feasible | #2903 |
| severe asthma | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| lowrisk patients | #2917 |
| leading death | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| 2400 | #2934 |
| risk stratification patients | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| exercise therapy | #2962 |
| followup | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| lecture | #2984 |
| declare | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| early recognition | #3025 |
| nested case | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| 2 4 | #3076 |
| subsequently | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| benchmark | #3110 |
| trimester | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| wallis | #3122 |
| oac | #3122 |
| lifelong | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 12 months | #3134 |
| 136 | #3134 |
| meta‐analysis | #3137 |
| 082 | #3142 |
| levels risk | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| pregnancy women | #3194 |
| diethylstilbestrol | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| therapy risk | #3199 |
| tenth | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| 153 | #3223 |
| intravenous infusion | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| 198 | #3251 |
| bivalirudin | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| scoring | #3255 |
| judgement | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| coumarin | #3289 |
| tumor markers | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| inpatients | #3344 |
| cerebrovascular disease | #3344 |
| 362 | #3349 |
| evaluating | #3349 |
| diagnosing | #3354 |
| spontaneous abortion | #3354 |
| 273 | #3355 |
| common complication | #3356 |
| diagnosis cancer | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| concluded | #3379 |
| humans lower | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| calf | #3389 |
| function patients | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| acute treatment | #3403 |
| 553 | #3403 |
| tunica | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| study risk | #3420 |
| surgical patients | #3420 |
| hypothesised | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| 34 | #3470 |
| differ | #3470 |
| intensive chemotherapy | #3471 |
| pregnancy complications | #3472 |
| patients receive | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| cancer metastasis | #3485 |
| antiphospholipid | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| inhibitors | #3506 |
| treat | #3506 |
| hemorrhagic complications | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| confirmed | #3522 |
| discusses | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| treated | #3619 |
| platelet function | #3619 |
| platelet activation | #3622 |
| interval | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| kappa | #3629 |
| q3 | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| bypass surgery | #3642 |
| undergo | #3642 |
| homozygote | #3642 |
| externally | #3645 |
| p006 | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| outcome administration | #3671 |
| optimal management | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| drug monitoring | #3721 |
| diagnostic process | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| randomised | #3754 |
| deterioration | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| total knee arthroplasty | #3789 |
| thyroid hormones | #3789 |
| aminoglycosides | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| 330 | #3815 |
| patients lung cancer | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| difference | #3890 |
| 351 | #3890 |
| 184 | #3890 |
| 10000 | #3902 |
| methylamines | #3903 |
| halflives | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| 405 | #3946 |
| case fatality | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| behalf | #3971 |
| austrian | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| flying | #3986 |
| unstable | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| natriuretic peptide | #4089 |
| oligosaccharides | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| activation | #4099 |
| cutoff | #4099 |
| indications | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 411 | #4212 |
| 485 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 289 | #4226 |
| 121 | #4226 |
| trough | #4229 |
| crosssectional analysis | #4230 |
| p0005 | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| cox regression | #4242 |
| patients mortality | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| potential risk factors | #4350 |
| managed | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| rapid | #4383 |
| minutes | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| concurrently | #4394 |
| slice | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| negative | #4407 |
| bowel diseases | #4407 |
| general | #4407 |
| 71 | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| proband | #4461 |
| cytomegalovirus infection | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| inadequate | #4487 |
| pancreatic cancer | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| comprises | #4503 |
| activation platelet | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| cerebrovascular disorders | #4571 |
| calculating | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| gradual | #4595 |
| eventually | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4000 | #4601 |
| 4 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| habitual | #4658 |
| 003 | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| ranging | #4698 |
| unchanged | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| chronic renal | #4775 |
| baseline patients | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| nonvalvular atrial fibrillation | #4870 |
| gpiib | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| antiplatelet therapy | #4891 |
| total | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| tests prognosis | #4906 |
| preparations | #4906 |
| served | #4910 |
| chlamydophila | #4913 |
| fmd | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| dose | #4976 |
| manufacturers | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| epoprostenol | #5009 |
| reminder | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| screening test | #5040 |
| 156 | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| relation | #5090 |
| hip fractures | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| bay | #5124 |
| vivo studies | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| 0018 | #5130 |
| ischaemic stroke | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| predispose | #5170 |
| 11 patients | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| articles | #5233 |
| emergencies | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| pooling | #5289 |
| 365 | #5289 |
| aware | #5300 |
| 36 patients | #5301 |
| thrombus | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| acute ischemic stroke | #5341 |
| reagent | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| 260 | #5497 |
| patient risk | #5497 |
| continuing | #5499 |
| discomfort | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| receptor1 | #5563 |
| established | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| reduce risk | #5573 |
| 46 | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| circulating levels | #5598 |
| equivalent | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| women pregnancy | #5857 |
| 290 | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| aged platelet | #5928 |
| 22 patients | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| 43 | #5962 |
| rcts | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| type iii | #6101 |
| topics | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 135 | #6340 |
| 63 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| factor gene | #6405 |
| roche | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| peripheral artery disease | #6501 |
| accuracy | #6501 |
| cancer cell | #6502 |
| incidence risk | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| 318 | #6524 |
| washout | #6524 |
| triiodothyronine | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| cochrane | #6532 |
| increased incidence | #6532 |
| highrisk patients | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| aspirin patients | #6540 |
| thirteen | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| hazard ratios | #6729 |
| recognised | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| reached | #6803 |
| premedication | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| adverse event | #6912 |
| disturbances | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| intensity | #6976 |
| 246 | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| betacoronavirus covid19 | #7104 |
| computed | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| cardiovascular disease cvd | #7210 |
| acting | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| vldl | #7250 |
| treatment children | #7250 |
| hematocrit | #7255 |
| 199 | #7257 |
| retrospective cohort study | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| sensitivity analysis | #7290 |
| modest | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| pectoris | #7338 |
| ischemic stroke | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| standardised | #7356 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| 191 | #7578 |
| cinahl | #7578 |
| comorbid | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| 110 | #7802 |
| manufacturer | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| label | #7828 |
| hormone replacement | #7828 |
| 31 patients | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| academic | #7878 |
| tramadol | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| preventable | #8051 |
| 600 | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| training | #8120 |
| patients heart | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| imaging studies | #8141 |
| investigational | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lists | #8250 |
| lowest | #8250 |
| version | #8260 |
| activated | #8264 |
| 125i | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| occur | #8415 |
| 28 patients | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| covariate | #8501 |
| evaluate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| adolescent | #8582 |
| 146 | #8582 |
| row | #8590 |
| thirty | #8596 |
| carotid arteries | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| 15 years | #8624 |
| fish oil | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| cardiovascular | #8756 |
| endovascular | #8756 |
| practical | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| proportional hazards | #8945 |
| signs symptoms | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| patients placebo | #9002 |
| options | #9002 |
| chemoprevention | #9005 |
| comprise | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| mps | #9080 |
| diagnose | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| time points | #9147 |
| valve prosthesis | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| rabbit | #9286 |
| positive | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| patients negative | #9355 |
| p0004 | #9355 |
| preceded | #9376 |
| loss | #9378 |
| higher incidence | #9380 |
| 014 | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| primary point | #9638 |
| kidney failure | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| easily | #9817 |
| precise | #9817 |
| nmol | #9828 |
| coa reductase | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| degradation | #9941 |
| 2003 | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| 12 hours | #9997 |
| pancreatic | #9997 |
| casecontrol studies | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| protective | #10045 |
| obstacles | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| worldwide | #10337 |
| 667 | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| antisense | #10583 |
| recurrences | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| concerned | #10674 |
| held | #10674 |
| pulmonary vascular | #10690 |
| discriminate | #10697 |
| term | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| airways | #10903 |
| diagnoses | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| ischemic | #11057 |
| neutropenia | #11057 |
| summarizes | #11062 |
| ethical | #11062 |
| attained | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| location | #11108 |
| inability | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| cerebrovascular | #11281 |
| humans kidney | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| occlusion | #11533 |
| placebo treatment | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| younger patients | #11624 |
| baseline | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| dietary intake | #12057 |
| thirds | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| guide | #12540 |
| requires | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| 45 | #12708 |
| prostatic | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| escalation | #13107 |
| cancer risk | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| vascular | #13708 |
| competence | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| explanation | #13773 |
| pelvic | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| focus | #14084 |
| situations | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| renal insufficiency | #14637 |
| statistics | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| validity | #14787 |
| independent predictor | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| copd | #15201 |
| decrease | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| women age | #15474 |
| randomised controlled trial | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| examination | #15813 |
| effectively | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| cooperative | #17262 |
| lung neoplasms | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| metastases | #18296 |
| ventricular function | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| persistent | #20562 |
| elisa | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| operative | #21137 |
| attenuated | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| majority | #21894 |
| 139 | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| naive | #23767 |
| adverse | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| commonly | #27411 |
| mass bmi | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Rapport d'exécution | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Connu pour Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Connu pour Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Connu pour Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Connu pour Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Connu pour Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Connu pour Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Connu pour Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Connu pour Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Connu pour Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Connu pour Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Connu pour Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Connu pour Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Connu pour Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Connu pour Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Des personnes clés pour Pulmonary Embolism
Top Kols dans le monde
Sélectionnez une phrase de recherche pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Impact expert
Concepts pour lesquelsHarry Roger Büllera une influence directe:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:Impact de Kol
Concepts liés au travail d'autres auteurs pour lesquelsfor which Harry Roger Büller a une influence:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
Est-ce votre profil? Réclamez votre profil Copier le lien ENCHED LIEN À VOTRE PROFIL |